{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:46:35Z","timestamp":1792125995285,"version":"4.4.0"},"reference-count":462,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02911-1","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:10:45Z","timestamp":1792123845000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Next-generation natural killer cell therapy: bench to bedside and beyond"],"prefix":"10.1038","volume":"11","author":[{"given":"Aiqi","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhai","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1193-7830","authenticated-orcid":false,"given":"Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8978-1987","authenticated-orcid":false,"given":"Aibin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1580-1014","authenticated-orcid":false,"given":"Ting","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9817-6674","authenticated-orcid":false,"given":"Wenbin","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"key":"2911_CR1","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/eji.1830050208","volume":"5","author":"R Kiessling","year":"1975","unstructured":"Kiessling, R., Klein, E. & Wigzell, H. \u201cNatural\u201d killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur. J. Immunol. 5, 112\u2013117 (1975).","journal-title":"Eur. J. Immunol."},{"key":"2911_CR2","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/ijc.2910160204","volume":"16","author":"RB Herberman","year":"1975","unstructured":"Herberman, R. B., Nunn, M. E. & Lavrin, D. H. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity. Int. J. Cancer. 16, 216\u2013229 (1975).","journal-title":"Int. J. Cancer."},{"key":"2911_CR3","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1146\/annurev.immunol.14.1.619","volume":"14","author":"A Moretta","year":"1996","unstructured":"Moretta, A. et al. Receptors for HLA class-I molecules in human natural killer cells. Annu. Rev. Immunol. 14, 619\u2013648 (1996).","journal-title":"Annu. Rev. Immunol."},{"key":"2911_CR4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1146\/annurev.immunol.19.1.197","volume":"19","author":"A Moretta","year":"2001","unstructured":"Moretta, A. et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu. Rev. Immunol. 19, 197\u2013223 (2001).","journal-title":"Annu. Rev. Immunol."},{"key":"2911_CR5","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/ni1582","volume":"9","author":"E Vivier","year":"2008","unstructured":"Vivier, E. et al. Functions of natural killer cells. Nat. Immunol. 9, 503\u2013510 (2008).","journal-title":"Nat. Immunol."},{"key":"2911_CR6","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/s41392-024-02005-w","volume":"9","author":"S Chen","year":"2024","unstructured":"Chen, S., Zhu, H. & Jounaidi, Y. Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization. Signal Transduct. Target. Ther. 9, 302 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2911_CR7","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1016\/j.ccell.2025.09.013","volume":"43","author":"A Biederstadt","year":"2025","unstructured":"Biederstadt, A. & Rezvani, K. Engineered natural killer cells for cancer therapy. Cancer Cell 43, 1987\u20132013 (2025).","journal-title":"Cancer Cell"},{"key":"2911_CR8","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41573-022-00413-7","volume":"21","author":"NA Maskalenko","year":"2022","unstructured":"Maskalenko, N. A., Zhigarev, D. & Campbell, K. S. Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders. Nat. Rev. Drug Discov. 21, 559\u2013577 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2911_CR9","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","volume":"105","author":"JS Miller","year":"2005","unstructured":"Miller, J. S. et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 105, 3051\u20133057 (2005).","journal-title":"Blood."},{"key":"2911_CR10","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1126\/science.1068440","volume":"295","author":"L Ruggeri","year":"2002","unstructured":"Ruggeri, L. et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 295, 2097\u20132100 (2002).","journal-title":"Science."},{"key":"2911_CR11","doi-asserted-by":"publisher","first-page":"357ra123","DOI":"10.1126\/scitranslmed.aaf2341","volume":"8","author":"R Romee","year":"2016","unstructured":"Romee, R. et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci. Transl. Med. 8, 357ra123 (2016).","journal-title":"Sci. Transl. Med."},{"key":"2911_CR12","doi-asserted-by":"publisher","first-page":"e154334","DOI":"10.1172\/JCI154334","volume":"132","author":"RM Shapiro","year":"2022","unstructured":"Shapiro, R. M. et al. Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse. J. Clin. Invest. 132, e154334 (2022).","journal-title":"J. Clin. Invest."},{"key":"2911_CR13","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu, E. et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N. Engl. J. Med. 382, 545\u2013553 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2911_CR14","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","volume":"30","author":"D Marin","year":"2024","unstructured":"Marin, D. et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B cell tumors: a phase 1\/2 trial. Nat. Med. 30, 772\u2013784 (2024).","journal-title":"Nat. Med."},{"key":"2911_CR15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0140-6736(24)02462-0","volume":"405","author":"A Ghobadi","year":"2025","unstructured":"Ghobadi, A. et al. Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial. Lancet. 405, 127\u2013136 (2025).","journal-title":"Lancet."},{"key":"2911_CR16","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1158\/2643-3230.BCD-25-0170","volume":"7","author":"A Anilkumar Sithara","year":"2026","unstructured":"Anilkumar Sithara, A. et al. Composition and functional state of T and NK cells in the extramedullary myeloma tumor microenvironment. Blood Cancer Discov 7, 250\u2013265 (2026).","journal-title":"Blood Cancer Discov"},{"key":"2911_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-08361-x","volume":"16","author":"X Yang","year":"2025","unstructured":"Yang, X. et al. Multidimensional plasticity of natural killer cells in tumours. Cell Death Dis 16, 916 (2025).","journal-title":"Cell Death Dis"},{"key":"2911_CR18","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1016\/j.cell.2023.07.034","volume":"186","author":"F Tang","year":"2023","unstructured":"Tang, F. et al. A pan-cancer single-cell panorama of human natural killer cells. Cell. 186, 4235\u20134251.e4220 (2023).","journal-title":"Cell."},{"key":"2911_CR19","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1016\/S0140-6736(25)01671-X","volume":"406","author":"J Gao","year":"2026","unstructured":"Gao, J. et al. Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China. Lancet. 406, 2968\u20132979 (2026).","journal-title":"Lancet."},{"key":"2911_CR20","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.ard.2025.07.028","volume":"84","author":"Y Fu","year":"2025","unstructured":"Fu, Y. et al. Genetically modified CD19-targeting IL-15 secreting NK cells for the treatment of systemic lupus erythematosus. Ann. Rheum. Dis. 84, 1811\u20131821 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"2911_CR21","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.1016\/j.cell.2025.05.038","volume":"188","author":"X Wang","year":"2025","unstructured":"Wang, X. et al. An iPSC-derived CD19\/BCMA CAR-NK therapy in a patient with systemic sclerosis. Cell. 188, 4225\u20134238.e4212 (2025).","journal-title":"Cell."},{"key":"2911_CR22","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1038\/s41590-024-01883-0","volume":"25","author":"L Rebuffet","year":"2024","unstructured":"Rebuffet, L. et al. High-dimensional single-cell analysis of human natural killer cell heterogeneity. Nat. Immunol. 25, 1474\u20131488 (2024).","journal-title":"Nat. Immunol."},{"key":"2911_CR23","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41587-025-02629-5","volume":"43","author":"M Tarannum","year":"2025","unstructured":"Tarannum, M. et al. Engineering innate immune cells for cancer immunotherapy. Nat. Biotechnol. 43, 516\u2013533 (2025).","journal-title":"Nat. Biotechnol."},{"key":"2911_CR24","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1016\/j.ccell.2025.07.021","volume":"43","author":"A Biederstadt","year":"2025","unstructured":"Biederstadt, A. et al. Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potency. Cancer Cell 43, 2069\u20132088.e2011 (2025).","journal-title":"Cancer Cell"},{"key":"2911_CR25","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/j.ccell.2025.05.011","volume":"43","author":"I Nikolic","year":"2025","unstructured":"Nikolic, I. et al. Enhancing anti-tumor immunity of natural killer cells through targeting IL-15R signaling. Cancer Cell 43, 2034\u20132050.e2011 (2025).","journal-title":"Cancer Cell"},{"key":"2911_CR26","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/s41586-025-09087-8","volume":"643","author":"H Rafei","year":"2025","unstructured":"Rafei, H. et al. CREM is a regulatory checkpoint of CAR and IL-15 signalling in NK cells. Nature. 643, 1076\u20131086 (2025).","journal-title":"Nature."},{"key":"2911_CR27","first-page":"652","volume":"8","author":"JH Gong","year":"1994","unstructured":"Gong, J. H., Maki, G. & Klingemann, H. G. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia. 8, 652\u2013658 (1994).","journal-title":"Leukemia."},{"key":"2911_CR28","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/sj.bmt.1704117","volume":"31","author":"G Maki","year":"2003","unstructured":"Maki, G., Tam, Y. K., Berkahn, L. & Klingemann, H. G. Ex vivo purging with NK-92 prior to autografting for chronic myelogenous leukemia. Bone Marrow Transplant 31, 1119\u20131125 (2003).","journal-title":"Bone Marrow Transplant"},{"key":"2911_CR29","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.1182\/blood-2013-10-532531","volume":"123","author":"V Bachanova","year":"2014","unstructured":"Bachanova, V. et al. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood. 123, 3855\u20133863 (2014).","journal-title":"Blood."},{"key":"2911_CR30","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s00262-017-2100-1","volume":"67","author":"V Bachanova","year":"2018","unstructured":"Bachanova, V. et al. Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells. Cancer Immunol. Immunother. 67, 483\u2013494 (2018).","journal-title":"Cancer Immunol. Immunother."},{"key":"2911_CR31","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1007\/s00262-022-03158-9","volume":"71","author":"CM Lim","year":"2022","unstructured":"Lim, C. M. et al. Phase I study of expanded natural killer cells in combination with cetuximab for recurrent\/metastatic nasopharyngeal carcinoma. Cancer Immunol. Immunother. 71, 2277\u20132286 (2022).","journal-title":"Cancer Immunol. Immunother."},{"key":"2911_CR32","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1182\/bloodadvances.2018028332","volume":"3","author":"S Cooley","year":"2019","unstructured":"Cooley, S. et al. First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia. Blood Adv 3, 1970\u20131980 (2019).","journal-title":"Blood Adv"},{"key":"2911_CR33","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.canlet.2018.02.033","volume":"422","author":"M Vela","year":"2018","unstructured":"Vela, M. et al. Haploidentical IL-15\/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia. Cancer Lett 422, 107\u2013117 (2018).","journal-title":"Cancer Lett"},{"key":"2911_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40164-024-00592-6","volume":"14","author":"R Huang","year":"2025","unstructured":"Huang, R. et al. Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed\/refractory AML: preclinical evaluation and phase I trial. Exp. Hematol. Oncol. 14, 1 (2025).","journal-title":"Exp. Hematol. Oncol."},{"key":"2911_CR35","doi-asserted-by":"publisher","first-page":"4509","DOI":"10.1016\/j.ymthe.2025.05.026","volume":"33","author":"B Li","year":"2025","unstructured":"Li, B. et al. Intraperitoneal infusion of NKG2D CAR-NK cells induces endogenous CD8(+) T cell activation in patients with advanced colorectal cancer. Mol. Ther. 33, 4509\u20134528 (2025).","journal-title":"Mol. Ther."},{"key":"2911_CR36","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/s43018-025-00940-3","volume":"6","author":"W Lei","year":"2025","unstructured":"Lei, W. et al. Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory\/relapsed large B cell lymphoma: a phase 1 trial. Nat. Cancer. 6, 786\u2013800 (2025).","journal-title":"Nat. Cancer."},{"key":"2911_CR37","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/MOH.0000000000000765","volume":"30","author":"C Schorr","year":"2023","unstructured":"Schorr, C., Krishnan, M. S. & Capitano, M. Deficits in our understanding of natural killer cell development in mouse and human. Curr. Opin. Hematol. 30, 106\u2013116 (2023).","journal-title":"Curr. Opin. Hematol."},{"key":"2911_CR38","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.1182\/blood-2010-04-281394","volume":"117","author":"B Grzywacz","year":"2011","unstructured":"Grzywacz, B. et al. Natural killer-cell differentiation by myeloid progenitors. Blood. 117, 3548\u20133558 (2011).","journal-title":"Blood."},{"key":"2911_CR39","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nri3365","volume":"13","author":"H Spits","year":"2013","unstructured":"Spits, H. et al. Innate lymphoid cells\u2014a proposal for uniform nomenclature. Nat. Rev. Immunol. 13, 145\u2013149 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"2911_CR40","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.cell.2018.07.017","volume":"174","author":"E Vivier","year":"2018","unstructured":"Vivier, E. et al. Innate lymphoid cells: 10 years on. Cell. 174, 1054\u20131066 (2018).","journal-title":"Cell."},{"key":"2911_CR41","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/s41590-024-01865-2","volume":"25","author":"Y Ding","year":"2024","unstructured":"Ding, Y. et al. Distinct developmental pathways generate functionally distinct populations of natural killer cells. Nat. Immunol. 25, 1183\u20131192 (2024).","journal-title":"Nat. Immunol."},{"key":"2911_CR42","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/s41590-024-01861-6","volume":"25","author":"Z Liang","year":"2024","unstructured":"Liang, Z. et al. Eomes expression identifies the early bone marrow precursor to classical NK cells. Nat. Immunol. 25, 1172\u20131182 (2024).","journal-title":"Nat. Immunol."},{"key":"2911_CR43","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.immuni.2011.11.016","volume":"36","author":"SM Gordon","year":"2012","unstructured":"Gordon, S. M. et al. The transcription factors T-bet and Eomes control key checkpoints of natural killer cell maturation. Immunity. 36, 55\u201367 (2012).","journal-title":"Immunity."},{"key":"2911_CR44","doi-asserted-by":"publisher","first-page":"610789","DOI":"10.3389\/fimmu.2021.610789","volume":"12","author":"X Wang","year":"2021","unstructured":"Wang, X. & Zhao, X. Y. Transcription factors associated with IL-15 cytokine signaling during NK cell development. Front. Immunol. 12, 610789 (2021).","journal-title":"Front. Immunol."},{"key":"2911_CR45","doi-asserted-by":"publisher","first-page":"568927","DOI":"10.3389\/fimmu.2020.568927","volume":"11","author":"V Schwane","year":"2020","unstructured":"Schwane, V. et al. Distinct signatures in the receptor repertoire discriminate CD56bright and CD56dim natural killer cells. Front. Immunol. 11, 568927 (2020).","journal-title":"Front. Immunol."},{"key":"2911_CR46","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1182\/blood-2010-04-282301","volume":"116","author":"S Lopez-Verges","year":"2010","unstructured":"Lopez-Verges, S. et al. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood. 116, 3865\u20133874 (2010).","journal-title":"Blood."},{"key":"2911_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11947-7","volume":"10","author":"C Yang","year":"2019","unstructured":"Yang, C. et al. Heterogeneity of human bone marrow and blood natural killer cells defined by single-cell transcriptome. Nat. Commun. 10, 3931 (2019).","journal-title":"Nat. Commun."},{"key":"2911_CR48","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/s41423-020-00574-8","volume":"18","author":"A Crinier","year":"2021","unstructured":"Crinier, A. et al. Single-cell profiling reveals the trajectories of natural killer cell differentiation in bone marrow and a stress signature induced by acute myeloid leukemia. Cell. Mol. Immunol. 18, 1290\u20131304 (2021).","journal-title":"Cell. Mol. Immunol."},{"key":"2911_CR49","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/nature07665","volume":"457","author":"JC Sun","year":"2009","unstructured":"Sun, J. C., Beilke, J. N. & Lanier, L. L. Adaptive immune features of natural killer cells. Nature. 457, 557\u2013561 (2009).","journal-title":"Nature."},{"key":"2911_CR50","doi-asserted-by":"publisher","first-page":"4751","DOI":"10.1182\/blood-2012-04-419283","volume":"120","author":"R Romee","year":"2012","unstructured":"Romee, R. et al. Cytokine activation induces human memory-like NK cells. Blood. 120, 4751\u20134760 (2012).","journal-title":"Blood."},{"key":"2911_CR51","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.immuni.2015.02.008","volume":"42","author":"H Schlums","year":"2015","unstructured":"Schlums, H. et al. Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function. Immunity. 42, 443\u2013456 (2015).","journal-title":"Immunity."},{"key":"2911_CR52","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/s41590-022-01327-7","volume":"23","author":"T Ruckert","year":"2022","unstructured":"Ruckert, T. et al. Clonal expansion and epigenetic inheritance of long-lasting NK cell memory. Nat. Immunol. 23, 1551\u20131563 (2022).","journal-title":"Nat. Immunol."},{"key":"2911_CR53","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/s41590-018-0082-6","volume":"19","author":"Q Hammer","year":"2018","unstructured":"Hammer, Q. et al. Peptide-specific recognition of human cytomegalovirus strains controls adaptive natural killer cells. Nat. Immunol. 19, 453\u2013463 (2018).","journal-title":"Nat. Immunol."},{"key":"2911_CR54","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/s41590-018-0176-1","volume":"19","author":"CM Lau","year":"2018","unstructured":"Lau, C. M. et al. Epigenetic control of innate and adaptive immune memory. Nat. Immunol. 19, 963\u2013972 (2018).","journal-title":"Nat. Immunol."},{"key":"2911_CR55","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1177\/17534259211001512","volume":"27","author":"AS Perera Molligoda Arachchige","year":"2021","unstructured":"Perera Molligoda Arachchige, A. S. Human NK cells: from development to effector functions. Innate Immun 27, 212\u2013229 (2021).","journal-title":"Innate Immun"},{"key":"2911_CR56","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41586-020-2071-9","volume":"579","author":"Z Zhang","year":"2020","unstructured":"Zhang, Z. et al. Gasdermin E suppresses tumour growth by activating anti-tumour immunity. Nature. 579, 415\u2013420 (2020).","journal-title":"Nature."},{"key":"2911_CR57","doi-asserted-by":"publisher","first-page":"647358","DOI":"10.3389\/fimmu.2021.647358","volume":"12","author":"MJ Shannon","year":"2021","unstructured":"Shannon, M. J. & Mace, E. M. Natural killer cell integrins and their functions in tissue residency. Front. Immunol. 12, 647358 (2021).","journal-title":"Front. Immunol."},{"key":"2911_CR58","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41392-022-01058-z","volume":"7","author":"GH Ran","year":"2022","unstructured":"Ran, G. H. et al. Natural killer cell homing and trafficking in tissues and tumors: from biology to application. Signal Transduct. Target. Ther. 7, 205 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2911_CR59","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.mucimm.2024.12.009","volume":"18","author":"BK Tatematsu","year":"2025","unstructured":"Tatematsu, B. K. & Sojka, D. K. Tissue-resident natural killer cells derived from conventional natural killer cells are regulated by progesterone in the uterus. Mucosal Immunol 18, 390\u2013401 (2025).","journal-title":"Mucosal Immunol"},{"key":"2911_CR60","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.cell.2020.01.022","volume":"180","author":"P Dogra","year":"2020","unstructured":"Dogra, P. et al. Tissue determinants of human NK cell development, function, and residence. Cell. 180, 749\u2013763.e713 (2020).","journal-title":"Cell."},{"key":"2911_CR61","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1007\/s11427-016-0334-2","volume":"59","author":"H Peng","year":"2016","unstructured":"Peng, H. & Tian, Z. Tissue-resident natural killer cells in the livers. Sci. China Life Sci 59, 1218\u20131223 (2016).","journal-title":"Sci. China Life Sci"},{"key":"2911_CR62","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.4049\/jimmunol.1402756","volume":"194","author":"N Marquardt","year":"2015","unstructured":"Marquardt, N. et al. Cutting edge: identification and characterization of human intrahepatic CD49a+ NK cells. J. Immunol. 194, 2467\u20132471 (2015).","journal-title":"J. Immunol."},{"key":"2911_CR63","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/nri.2016.34","volume":"16","author":"NK Bjorkstrom","year":"2016","unstructured":"Bjorkstrom, N. K., Ljunggren, H. G. & Michaelsson, J. Emerging insights into natural killer cells in human peripheral tissues. Nat. Rev. Immunol. 16, 310\u2013320 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"2911_CR64","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.immuni.2023.11.018","volume":"57","author":"T Torcellan","year":"2024","unstructured":"Torcellan, T. et al. Circulating NK cells establish tissue residency upon acute infection of skin and mediate accelerated effector responses to secondary infection. Immunity. 57, 124\u2013140.e127 (2024).","journal-title":"Immunity."},{"key":"2911_CR65","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/nm1452","volume":"12","author":"J Hanna","year":"2006","unstructured":"Hanna, J. et al. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat. Med. 12, 1065\u20131074 (2006).","journal-title":"Nat. Med."},{"key":"2911_CR66","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.it.2011.06.013","volume":"32","author":"P Vacca","year":"2011","unstructured":"Vacca, P., Moretta, L., Moretta, A. & Mingari, M. C. Origin, phenotype and function of human natural killer cells in pregnancy. Trends Immunol 32, 517\u2013523 (2011).","journal-title":"Trends Immunol"},{"key":"2911_CR67","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3389\/fimmu.2019.00170","volume":"10","author":"P Vacca","year":"2019","unstructured":"Vacca, P., Chiossone, L., Mingari, M. C. & Moretta, L. Heterogeneity of NK cells and other innate lymphoid cells in human and murine decidua. Front. Immunol. 10, 170 (2019).","journal-title":"Front. Immunol."},{"key":"2911_CR68","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1002\/JLB.MR0718-260R","volume":"105","author":"CM Gardiner","year":"2019","unstructured":"Gardiner, C. M. NK cell metabolism. J. Leukoc. Biol. 105, 1235\u20131242 (2019).","journal-title":"J. Leukoc. Biol."},{"key":"2911_CR69","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/ni.3838","volume":"18","author":"N Assmann","year":"2017","unstructured":"Assmann, N. et al. Srebp-controlled glucose metabolism is essential for NK cell functional responses. Nat. Immunol. 18, 1197\u20131206 (2017).","journal-title":"Nat. Immunol."},{"key":"2911_CR70","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.4049\/jimmunol.1501783","volume":"196","author":"SE Keating","year":"2016","unstructured":"Keating, S. E. et al. Metabolic reprogramming supports IFN-gamma production by CD56bright NK cells. J. Immunol. 196, 2552\u20132560 (2016).","journal-title":"J. Immunol."},{"key":"2911_CR71","doi-asserted-by":"publisher","first-page":"e00020","DOI":"10.1097\/IN9.0000000000000020","volume":"5","author":"H Sohn","year":"2023","unstructured":"Sohn, H. & Cooper, M. A. Metabolic regulation of NK cell function: implications for immunotherapy. Immunometabolism 5, e00020 (2023).","journal-title":"Immunometabolism"},{"key":"2911_CR72","doi-asserted-by":"publisher","first-page":"619195","DOI":"10.3389\/fimmu.2021.619195","volume":"12","author":"Z Wang","year":"2021","unstructured":"Wang, Z. et al. IL-10 enhances human natural killer cell effector functions via metabolic reprogramming regulated by mTORC1 signaling. Front. Immunol. 12, 619195 (2021).","journal-title":"Front. Immunol."},{"key":"2911_CR73","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1182\/blood-2016-02-698027","volume":"128","author":"Y Mao","year":"2016","unstructured":"Mao, Y. et al. IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells. Blood. 128, 1475\u20131489 (2016).","journal-title":"Blood."},{"key":"2911_CR74","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.4049\/jimmunol.1401558","volume":"193","author":"RP Donnelly","year":"2014","unstructured":"Donnelly, R. P. et al. mTORC1-dependent metabolic reprogramming is a prerequisite for NK cell effector function. J. Immunol. 193, 4477\u20134484 (2014).","journal-title":"J. Immunol."},{"key":"2911_CR75","doi-asserted-by":"publisher","first-page":"104859","DOI":"10.1016\/j.critrevonc.2025.104859","volume":"215","author":"P Yang","year":"2025","unstructured":"Yang, P. et al. Metabolic reprogramming of NK cells drives anti-tumor immunity. Crit. Rev. Oncol. Hematol. 215, 104859 (2025).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"2911_CR76","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/s41590-025-02178-8","volume":"26","author":"J Jin","year":"2025","unstructured":"Jin, J. et al. Targeting lactylation reinforces NK cell cytotoxicity within the tumor microenvironment. Nat. Immunol. 26, 1099\u20131112 (2025).","journal-title":"Nat. Immunol."},{"key":"2911_CR77","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.it.2004.09.008","volume":"25","author":"L Moretta","year":"2004","unstructured":"Moretta, L. et al. Different checkpoints in human NK-cell activation. Trends Immunol 25, 670\u2013676 (2004).","journal-title":"Trends Immunol"},{"key":"2911_CR78","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1002\/eji.202049028","volume":"51","author":"L Quatrini","year":"2021","unstructured":"Quatrini, L. et al. Human NK cells, their receptors and function. Eur. J. Immunol. 51, 1566\u20131579 (2021).","journal-title":"Eur. J. Immunol."},{"key":"2911_CR79","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1084\/jem.20021127","volume":"197","author":"HW Chan","year":"2003","unstructured":"Chan, H. W. et al. DNA methylation maintains allele-specific KIR gene expression in human natural killer cells. J. Exp. Med. 197, 245\u2013255 (2003).","journal-title":"J. Exp. Med."},{"key":"2911_CR80","doi-asserted-by":"publisher","first-page":"e1010114","DOI":"10.1371\/journal.pcbi.1010114","volume":"18","author":"RK Grewal","year":"2022","unstructured":"Grewal, R. K. & Das, J. Spatially resolved in silico modeling of NKG2D signaling kinetics suggests a key role of NKG2D and Vav1 Co-clustering in generating natural killer cell activation. PLoS Comput. Biol. 18, e1010114 (2022).","journal-title":"PLoS Comput. Biol."},{"key":"2911_CR81","doi-asserted-by":"publisher","first-page":"e2114134119","DOI":"10.1073\/pnas.2114134119","volume":"119","author":"S Ma","year":"2022","unstructured":"Ma, S. et al. PDGF-D-PDGFR\u03b2 signaling enhances IL-15-mediated human natural killer cell survival. Proc. Natl. Acad. Sci. USA. 119, e2114134119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"2911_CR82","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.stem.2020.05.008","volume":"27","author":"H Zhu","year":"2020","unstructured":"Zhu, H. et al. Metabolic reprograming via deletion of CISH in human iPSC-derived NK cells promotes in vivo persistence and enhances anti-tumor activity. Cell Stem Cell 27, 224\u2013237.e226 (2020).","journal-title":"Cell Stem Cell"},{"key":"2911_CR83","doi-asserted-by":"publisher","first-page":"eabn7993","DOI":"10.1126\/sciimmunol.abn7993","volume":"8","author":"S Ma","year":"2023","unstructured":"Ma, S. et al. An XBP1s-PIM-2 positive feedback loop controls IL-15-mediated survival of natural killer cells. Sci. Immunol. 8, eabn7993 (2023).","journal-title":"Sci. Immunol."},{"key":"2911_CR84","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41590-018-0265-1","volume":"20","author":"Y Wang","year":"2019","unstructured":"Wang, Y. et al. The IL-15-AKT-XBP1s signaling pathway contributes to effector functions and survival in human NK cells. Nat. Immunol. 20, 10\u201317 (2019).","journal-title":"Nat. Immunol."},{"key":"2911_CR85","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1084\/jem.20111760","volume":"209","author":"JC Sun","year":"2012","unstructured":"Sun, J. C. et al. Proinflammatory cytokine signaling required for the generation of natural killer cell memory. J. Exp. Med. 209, 947\u2013954 (2012).","journal-title":"J. Exp. Med."},{"key":"2911_CR86","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.4049\/jimmunol.1700416","volume":"200","author":"S Madera","year":"2018","unstructured":"Madera, S. et al. Cutting edge: divergent requirement of T-Box transcription factors in effector and memory NK cells. J. Immunol. 200, 1977\u20131981 (2018).","journal-title":"J. Immunol."},{"key":"2911_CR87","doi-asserted-by":"publisher","first-page":"eaan3796","DOI":"10.1126\/sciimmunol.aan3796","volume":"2","author":"M Rapp","year":"2017","unstructured":"Rapp, M. et al. Core-binding factor \u03b2 and Runx transcription factors promote adaptive natural killer cell responses. Sci Immunol. 2, eaan3796 (2017).","journal-title":"Sci Immunol."},{"key":"2911_CR88","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.4049\/jimmunol.181.6.3784","volume":"181","author":"R Trotta","year":"2008","unstructured":"Trotta, R. et al. TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. J. Immunol. 181, 3784\u20133792 (2008).","journal-title":"J. Immunol."},{"key":"2911_CR89","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40164-025-00618-7","volume":"14","author":"P Zhang","year":"2025","unstructured":"Zhang, P. et al. CD28 is superior to 4-1BB costimulation in generating CAR-NK cells for tumor immunotherapy. Exp. Hematol. Oncol. 14, 28 (2025).","journal-title":"Exp. Hematol. Oncol."},{"key":"2911_CR90","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13045-019-0732-7","volume":"12","author":"Y Xu","year":"2019","unstructured":"Xu, Y. et al. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies. J. Hematol. Oncol. 12, 49 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"2911_CR91","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3389\/fimmu.2015.00601","volume":"6","author":"C Chester","year":"2015","unstructured":"Chester, C., Fritsch, K. & Kohrt, H. E. Natural killer cell immunomodulation: targeting activating, inhibitory, and co-stimulatory receptor signaling for cancer immunotherapy. Front. Immunol. 6, 601 (2015).","journal-title":"Front. Immunol."},{"key":"2911_CR92","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1158\/2159-8290.CD-24-0096","volume":"14","author":"S Acharya","year":"2024","unstructured":"Acharya, S. et al. CD28 costimulation augments CAR signaling in NK cells via the LCK\/CD3zeta\/ZAP70 signaling axis. Cancer Discov 14, 1879\u20131900 (2024).","journal-title":"Cancer Discov"},{"key":"2911_CR93","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/nature03847","volume":"436","author":"S Kim","year":"2005","unstructured":"Kim, S. et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature. 436, 709\u2013713 (2005).","journal-title":"Nature."},{"key":"2911_CR94","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/cmi.2016.26","volume":"14","author":"Y He","year":"2017","unstructured":"He, Y. & Tian, Z. NK cell education via nonclassical MHC and non-MHC ligands. Cell. Mol. Immunol. 14, 321\u2013330 (2017).","journal-title":"Cell. Mol. Immunol."},{"key":"2911_CR95","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/0167-5699(90)90097-S","volume":"11","author":"HG Ljunggren","year":"1990","unstructured":"Ljunggren, H. G. & Karre, K. In search of the \u2018missing self\u2019: MHC molecules and NK cell recognition. Immunol. Today. 11, 237\u2013244 (1990).","journal-title":"Immunol. Today."},{"key":"2911_CR96","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/nature03884","volume":"436","author":"S Gasser","year":"2005","unstructured":"Gasser, S., Orsulic, S., Brown, E. J. & Raulet, D. H. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature. 436, 1186\u20131190 (2005).","journal-title":"Nature."},{"key":"2911_CR97","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/35059110","volume":"409","author":"O Mandelboim","year":"2001","unstructured":"Mandelboim, O. et al. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature. 409, 1055\u20131060 (2001).","journal-title":"Nature."},{"key":"2911_CR98","doi-asserted-by":"publisher","first-page":"0723","DOI":"10.34133\/research.0723","volume":"8","author":"A Lin","year":"2025","unstructured":"Lin, A. et al. Natural killer cell immune checkpoints and their therapeutic targeting in cancer treatment. Research. 8, 0723 (2025).","journal-title":"Research."},{"key":"2911_CR99","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/cac2.12394","volume":"43","author":"F Ghaedrahmati","year":"2023","unstructured":"Ghaedrahmati, F., Esmaeil, N. & Abbaspour, M. Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors. Cancer Commun 43, 177\u2013213 (2023).","journal-title":"Cancer Commun"},{"key":"2911_CR100","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1016\/j.cell.2024.03.039","volume":"187","author":"Y Li","year":"2024","unstructured":"Li, Y. et al. IGSF8 is an innate immune checkpoint and cancer immunotherapy target. Cell. 187, 2703\u20132716.e2723 (2024).","journal-title":"Cell."},{"key":"2911_CR101","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature24293","volume":"551","author":"M Molgora","year":"2017","unstructured":"Molgora, M. et al. IL-1R8 is a checkpoint in NK cells regulating anti-tumour and anti-viral activity. Nature. 551, 110\u2013114 (2017).","journal-title":"Nature."},{"key":"2911_CR102","doi-asserted-by":"publisher","first-page":"eadr9395","DOI":"10.1126\/sciadv.adr9395","volume":"11","author":"X Hui","year":"2025","unstructured":"Hui, X. et al. GPR132 regulates the function of NK cells through the Galphas\/CSK\/ZAP70\/NF-kappaB signaling pathway as a potential immune checkpoint. Sci. Adv. 11, eadr9395 (2025).","journal-title":"Sci. Adv."},{"key":"2911_CR103","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41590-026-02471-0","volume":"27","author":"P Sun","year":"2026","unstructured":"Sun, P. et al. Targeting NK cell CLEC12B enhances cancer immunotherapy. Nat. Immunol. 27, 985\u2013999 (2026).","journal-title":"Nat. Immunol."},{"key":"2911_CR104","doi-asserted-by":"publisher","first-page":"eabi6515","DOI":"10.1126\/sciadv.abi6515","volume":"7","author":"J Bi","year":"2021","unstructured":"Bi, J. et al. TIPE2 is a checkpoint of natural killer cell maturation and antitumor immunity. Sci. Adv. 7, eabi6515 (2021).","journal-title":"Sci. Adv."},{"key":"2911_CR105","doi-asserted-by":"publisher","first-page":"e2207499","DOI":"10.1002\/advs.202207499","volume":"10","author":"J Bi","year":"2023","unstructured":"Bi, J. et al. Checkpoint TIPE2 limits the helper functions of NK cells in supporting antitumor CD8(+) T cells. Adv. Sci. 10, e2207499 (2023).","journal-title":"Adv. Sci."},{"key":"2911_CR106","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1093\/jimmun\/vkaf012","volume":"214","author":"AJ Millan","year":"2025","unstructured":"Millan, A. J. et al. SYK negatively regulates ITAM-mediated human NK cell signaling and CD19-CAR NK cell efficacy. J. Immunol. 214, 384\u2013398 (2025).","journal-title":"J. Immunol."},{"key":"2911_CR107","doi-asserted-by":"publisher","first-page":"115708","DOI":"10.1016\/j.celrep.2025.115708","volume":"44","author":"F Yang","year":"2025","unstructured":"Yang, F. et al. GATA1-mediated Notch signaling augment antitumor immunity of CD11b(+)CD27(-) natural killer cells maturation via BCL9\/beta-catenin signal. Cell Rep. 44, 115708 (2025).","journal-title":"Cell Rep."},{"key":"2911_CR108","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/ni1242","volume":"6","author":"R Roncagalli","year":"2005","unstructured":"Roncagalli, R. et al. Negative regulation of natural killer cell function by EAT-2, a SAP-related adaptor. Nat. Immunol. 6, 1002\u20131010 (2005).","journal-title":"Nat. Immunol."},{"key":"2911_CR109","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/s41590-025-02103-z","volume":"26","author":"A Rea","year":"2025","unstructured":"Rea, A. et al. Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGFbeta and activin A suppression. Nat. Immunol. 26, 582\u2013594 (2025).","journal-title":"Nat. Immunol."},{"key":"2911_CR110","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-68661-4","volume":"17","author":"R Wang","year":"2026","unstructured":"Wang, R. et al. SAMSN1 restrains NK cell mediated anti-tumor immunity in hepatocellular carcinoma. Nat Commun. 17, 1903 (2026).","journal-title":"Nat Commun."},{"key":"2911_CR111","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54355-2","volume":"15","author":"F Portale","year":"2024","unstructured":"Portale, F. et al. C\/EBPbeta-dependent autophagy inhibition hinders NK cell function in cancer. Nat. Commun. 15, 10343 (2024).","journal-title":"Nat. Commun."},{"key":"2911_CR112","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/icb.2013.96","volume":"92","author":"EM Mace","year":"2014","unstructured":"Mace, E. M. et al. Cell biological steps and checkpoints in accessing NK cell cytotoxicity. Immunol. Cell Biol. 92, 245\u2013255 (2014).","journal-title":"Immunol. Cell Biol."},{"key":"2911_CR113","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1091\/mbc.e09-11-0930","volume":"21","author":"AN Mentlik","year":"2010","unstructured":"Mentlik, A. N., Sanborn, K. B., Holzbaur, E. L. & Orange, J. S. Rapid lytic granule convergence to the MTOC in natural killer cells is dependent on dynein but not cytolytic commitment. Mol. Biol. Cell. 21, 2241\u20132256 (2010).","journal-title":"Mol. Biol. Cell."},{"key":"2911_CR114","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1038\/s41587-022-01650-2","volume":"41","author":"PJ Chockley","year":"2023","unstructured":"Chockley, P. J. et al. Synapse-tuned CARs enhance immune cell anti-tumor activity. Nat. Biotechnol. 41, 1434\u20131445 (2023).","journal-title":"Nat. Biotechnol."},{"key":"2911_CR115","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1084\/jem.20181454","volume":"216","author":"I Prager","year":"2019","unstructured":"Prager, I. et al. NK cells switch from granzyme B to death receptor-mediated cytotoxicity during serial killing. J. Exp. Med. 216, 2113\u20132127 (2019).","journal-title":"J. Exp. Med."},{"key":"2911_CR116","doi-asserted-by":"publisher","first-page":"6488","DOI":"10.1073\/pnas.1221312110","volume":"110","author":"PJ Choi","year":"2013","unstructured":"Choi, P. J. & Mitchison, T. J. Imaging burst kinetics and spatial coordination during serial killing by single natural killer cells. Proc. Natl. Acad. Sci. USA. 110, 6488\u20136493 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"2911_CR117","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.cell.2018.11.045","volume":"176","author":"PL Collins","year":"2019","unstructured":"Collins, P. L. et al. Gene regulatory programs conferring phenotypic identities to human NK cells. Cell. 176, 348\u2013360.e312 (2019).","journal-title":"Cell."},{"key":"2911_CR118","doi-asserted-by":"publisher","first-page":"e47605","DOI":"10.7554\/eLife.47605","volume":"8","author":"E Park","year":"2019","unstructured":"Park, E. et al. Toxoplasma gondii infection drives conversion of NK cells into ILC1-like cells. Elife. 8, e47605 (2019).","journal-title":"Elife."},{"key":"2911_CR119","doi-asserted-by":"publisher","first-page":"e09989","DOI":"10.1002\/advs.202509989","volume":"12","author":"H Shen","year":"2025","unstructured":"Shen, H. et al. Lactate metabolic reprogramming mediated by CircRNA-LDHA complex facilitates innate immune evasion of liver cancer. Adv. Sci. 12, e09989 (2025).","journal-title":"Adv. Sci."},{"key":"2911_CR120","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41580-019-0159-6","volume":"20","author":"MVC Greenberg","year":"2019","unstructured":"Greenberg, M. V. C. & Bourc\u2019his, D. The diverse roles of DNA methylation in mammalian development and disease. Nat. Rev. Mol. Cell Biol. 20, 590\u2013607 (2019).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2911_CR121","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1002\/eji.201344072","volume":"44","author":"M Luetke-Eversloh","year":"2014","unstructured":"Luetke-Eversloh, M. et al. NK cells gain higher IFN-gamma competence during terminal differentiation. Eur. J. Immunol. 44, 2074\u20132084 (2014).","journal-title":"Eur. J. Immunol."},{"key":"2911_CR122","doi-asserted-by":"publisher","first-page":"418","DOI":"10.4049\/jimmunol.180.1.418","volume":"180","author":"S Santourlidis","year":"2008","unstructured":"Santourlidis, S., Graffmann, N., Christ, J. & Uhrberg, M. Lineage-specific transition of histone signatures in the killer cell IG-like receptor locus from hematopoietic progenitor to NK cells. J. Immunol. 180, 418\u2013425 (2008).","journal-title":"J. Immunol."},{"key":"2911_CR123","doi-asserted-by":"publisher","first-page":"414","DOI":"10.4049\/jimmunol.177.1.414","volume":"177","author":"SL Rogers","year":"2006","unstructured":"Rogers, S. L., Rouhi, A., Takei, F. & Mager, D. L. A role for DNA hypomethylation and histone acetylation in maintaining allele-specific expression of mouse NKG2A in developing and mature NK cells. J. Immunol. 177, 414\u2013421 (2006).","journal-title":"J. Immunol."},{"key":"2911_CR124","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1146\/annurev.immunol.23.021704.115526","volume":"23","author":"LL Lanier","year":"2005","unstructured":"Lanier, L. L. NK cell recognition. Annu. Rev. Immunol. 23, 225\u2013274 (2005).","journal-title":"Annu. Rev. Immunol."},{"key":"2911_CR125","doi-asserted-by":"publisher","first-page":"4253","DOI":"10.4049\/jimmunol.169.8.4253","volume":"169","author":"S Santourlidis","year":"2002","unstructured":"Santourlidis, S. et al. Crucial role of DNA methylation in determination of clonally distributed killer cell Ig-like receptor expression patterns in NK cells. J. Immunol. 169, 4253\u20134261 (2002).","journal-title":"J. Immunol."},{"key":"2911_CR126","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.molimm.2004.07.029","volume":"42","author":"M Uhrberg","year":"2005","unstructured":"Uhrberg, M. Shaping the human NK cell repertoire: an epigenetic glance at KIR gene regulation. Mol. Immunol. 42, 471\u2013475 (2005).","journal-title":"Mol. Immunol."},{"key":"2911_CR127","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36193-w","volume":"14","author":"M Boy","year":"2023","unstructured":"Boy, M. et al. Myelodysplastic Syndrome associated TET2 mutations affect NK cell function and genome methylation. Nat. Commun. 14, 588 (2023).","journal-title":"Nat. Commun."},{"key":"2911_CR128","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.2217\/bmm-2019-0102","volume":"13","author":"NH Zhao","year":"2019","unstructured":"Zhao, N. H. et al. Diagnostic value of NKG2D promoter methylation in hepatitis B virus-associated hepatocellular carcinoma. Biomark. Med. 13, 1093\u20131105 (2019).","journal-title":"Biomark. Med."},{"key":"2911_CR129","doi-asserted-by":"publisher","first-page":"e1004441","DOI":"10.1371\/journal.ppat.1004441","volume":"10","author":"M Luetke-Eversloh","year":"2014","unstructured":"Luetke-Eversloh, M. et al. Human cytomegalovirus drives epigenetic imprinting of the IFNG locus in NKG2Chi natural killer cells. PLoS Pathog 10, e1004441 (2014).","journal-title":"PLoS Pathog"},{"key":"2911_CR130","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11033-024-10181-9","volume":"52","author":"Y Li","year":"2024","unstructured":"Li, Y. et al. DNMT1 inhibition improves the activity of memory-like natural killer cells by enhancing the level of autophagy. Mol. Biol. Rep. 52, 68 (2024).","journal-title":"Mol. Biol. Rep."},{"key":"2911_CR131","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/cr.2011.22","volume":"21","author":"AJ Bannister","year":"2011","unstructured":"Bannister, A. J. & Kouzarides, T. Regulation of chromatin by histone modifications. Cell Res 21, 381\u2013395 (2011).","journal-title":"Cell Res"},{"key":"2911_CR132","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cell.2007.02.005","volume":"128","author":"T Kouzarides","year":"2007","unstructured":"Kouzarides, T. Chromatin modifications and their function. Cell. 128, 693\u2013705 (2007).","journal-title":"Cell."},{"key":"2911_CR133","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.molcel.2012.11.006","volume":"48","author":"JC Black","year":"2012","unstructured":"Black, J. C., Van Rechem, C. & Whetstine, J. R. Histone lysine methylation dynamics: establishment, regulation, and biological impact. Mol. Cell. 48, 491\u2013507 (2012).","journal-title":"Mol. Cell."},{"key":"2911_CR134","doi-asserted-by":"publisher","first-page":"17095","DOI":"10.1073\/pnas.0502129102","volume":"102","author":"S Chang","year":"2005","unstructured":"Chang, S. & Aune, T. M. Histone hyperacetylated domains across the Ifng gene region in natural killer cells and T cells. Proc. Natl. Acad. Sci. USA. 102, 17095\u201317100 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"2911_CR135","doi-asserted-by":"publisher","first-page":"66","DOI":"10.4161\/epi.23115","volume":"8","author":"A Fernandez-Sanchez","year":"2013","unstructured":"Fernandez-Sanchez, A. et al. DNA demethylation and histone H3K9 acetylation determine the active transcription of the NKG2D gene in human CD8+ T and NK cells. Epigenetics. 8, 66\u201378 (2013).","journal-title":"Epigenetics."},{"key":"2911_CR136","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1074\/jbc.RA117.000698","volume":"293","author":"A Cribbs","year":"2018","unstructured":"Cribbs, A. et al. Inhibition of histone H3K27 demethylases selectively modulates inflammatory phenotypes of natural killer cells. J. Biol. Chem. 293, 2422\u20132437 (2018).","journal-title":"J. Biol. Chem."},{"key":"2911_CR137","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.celrep.2016.03.035","volume":"15","author":"D Zhao","year":"2016","unstructured":"Zhao, D. et al. H3K4me3 demethylase Kdm5a is required for NK cell activation by associating with p50 to suppress SOCS1. Cell Rep. 15, 288\u2013299 (2016).","journal-title":"Cell Rep."},{"key":"2911_CR138","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1016\/j.celrep.2019.11.043","volume":"29","author":"O Rasid","year":"2019","unstructured":"Rasid, O. et al. H3K4me1 supports memory-like NK cells induced by systemic inflammation. Cell Rep 29, 3933\u20133945.e3933 (2019).","journal-title":"Cell Rep"},{"key":"2911_CR139","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00018-024-05285-1","volume":"81","author":"F Guo","year":"2024","unstructured":"Guo, F. et al. CircARAP2 controls sMICA-induced NK cell desensitization by erasing CTCF\/PRC2-induced suppression in early endosome marker RAB5A. Cell. Mol. Life Sci. 81, 307 (2024).","journal-title":"Cell. Mol. Life Sci."},{"key":"2911_CR140","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1111\/febs.13614","volume":"283","author":"A Maity","year":"2016","unstructured":"Maity, A. & Das, B. N6-methyladenosine modification in mRNA: machinery, function and implications for health and diseases. FEBS J 283, 1607\u20131630 (2016).","journal-title":"FEBS J"},{"key":"2911_CR141","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1159\/000534162","volume":"15","author":"Y Teng","year":"2023","unstructured":"Teng, Y., Yi, J., Chen, J. & Yang, L. N6-methyladenosine (m6A) modification in natural immune cell-mediated inflammatory diseases. J. Innate Immun. 15, 804\u2013821 (2023).","journal-title":"J. Innate Immun."},{"key":"2911_CR142","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25803-0","volume":"12","author":"H Song","year":"2021","unstructured":"Song, H. et al. METTL3-mediated m(6)A RNA methylation promotes the anti-tumour immunity of natural killer cells. Nat. Commun. 12, 5522 (2021).","journal-title":"Nat. Commun."},{"key":"2911_CR143","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1158\/2326-6066.CIR-23-0339","volume":"12","author":"M Meng","year":"2024","unstructured":"Meng, M. et al. mTOR signaling promotes rapid m6A mRNA methylation to regulate NK-cell activation and effector functions. Cancer Immunol. Res. 12, 1039\u20131057 (2024).","journal-title":"Cancer Immunol. Res."},{"key":"2911_CR144","doi-asserted-by":"crossref","unstructured":"Ma, S. et al. The RNA m6A reader YTHDF2 controls NK cell antitumor and antiviral immunity. J. Exp. Med. 218, (2021).","DOI":"10.1084\/jem.20210279"},{"key":"2911_CR145","doi-asserted-by":"publisher","first-page":"101833","DOI":"10.1016\/j.gendis.2025.101833","volume":"13","author":"D Zhang","year":"2026","unstructured":"Zhang, D. et al. The role of long non-coding RNAs in NK cell biology and diseases. Genes Dis 13, 101833 (2026).","journal-title":"Genes Dis"},{"key":"2911_CR146","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","volume":"136","author":"DP Bartel","year":"2009","unstructured":"Bartel, D. P. MicroRNAs: target recognition and regulatory functions. Cell. 136, 215\u2013233 (2009).","journal-title":"Cell."},{"key":"2911_CR147","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.4049\/jimmunol.1500949","volume":"195","author":"RP Sullivan","year":"2015","unstructured":"Sullivan, R. P. et al. MicroRNA-15\/16 antagonizes Myb to control NK cell maturation. J. Immunol. 195, 2806\u20132817 (2015).","journal-title":"J. Immunol."},{"key":"2911_CR148","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1084\/jem.20111386","volume":"208","author":"NA Bezman","year":"2011","unstructured":"Bezman, N. A., Chakraborty, T., Bender, T. & Lanier, L. L. miR-150 regulates the development of NK and iNKT cells. J. Exp. Med. 208, 2717\u20132731 (2011).","journal-title":"J. Exp. Med."},{"key":"2911_CR149","doi-asserted-by":"publisher","first-page":"6171","DOI":"10.4049\/jimmunol.1100835","volume":"187","author":"F Cichocki","year":"2011","unstructured":"Cichocki, F. et al. Cutting edge: microRNA-181 promotes human NK cell development by regulating Notch signaling. J. Immunol. 187, 6171\u20136175 (2011).","journal-title":"J. Immunol."},{"key":"2911_CR150","doi-asserted-by":"publisher","first-page":"4404","DOI":"10.1172\/JCI85413","volume":"126","author":"BL Mundy-Bosse","year":"2016","unstructured":"Mundy-Bosse, B. L. et al. MicroRNA-29b mediates altered innate immune development in acute leukemia. J. Clin. Invest. 126, 4404\u20134416 (2016).","journal-title":"J. Clin. Invest."},{"key":"2911_CR151","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42182-w","volume":"14","author":"C Rozmanic","year":"2023","unstructured":"Rozmanic, C. et al. Perinatal murine cytomegalovirus infection reshapes the transcriptional profile and functionality of NK cells. Nat. Commun. 14, 6412 (2023).","journal-title":"Nat. Commun."},{"key":"2911_CR152","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.immuni.2017.08.012","volume":"47","author":"WK Mowel","year":"2017","unstructured":"Mowel, W. K. et al. Group 1 innate lymphoid cell lineage identity is determined by a cis-regulatory element marked by a long non-coding RNA. Immunity. 47, 435\u2013449.e438 (2017).","journal-title":"Immunity."},{"key":"2911_CR153","doi-asserted-by":"publisher","first-page":"211","DOI":"10.4049\/jimmunol.1200609","volume":"189","author":"P Wang","year":"2012","unstructured":"Wang, P. et al. Identification of resting and type I IFN-activated human NK cell miRNomes reveals microRNA-378 and microRNA-30e as negative regulators of NK cell cytotoxicity. J. Immunol. 189, 211\u2013221 (2012).","journal-title":"J. Immunol."},{"key":"2911_CR154","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jaci.2014.02.018","volume":"134","author":"N Kim","year":"2014","unstructured":"Kim, N. et al. MicroRNA-150 regulates the cytotoxicity of natural killers by targeting perforin-1. J. Allergy Clin. Immunol. 134, 195\u2013203 (2014).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2911_CR155","doi-asserted-by":"publisher","first-page":"5476","DOI":"10.1182\/blood-2011-04-347526","volume":"118","author":"TD Kim","year":"2011","unstructured":"Kim, T. D. et al. Human microRNA-27a* targets Prf1 and GzmB expression to regulate NK-cell cytotoxicity. Blood. 118, 5476\u20135486 (2011).","journal-title":"Blood."},{"key":"2911_CR156","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3389\/fimmu.2018.00293","volume":"9","author":"H Wang","year":"2018","unstructured":"Wang, H. et al. Regulation of human natural killer Cell IFN-gamma production by microRNA-146a via targeting the NF-kappaB signaling pathway. Front. Immunol. 9, 293 (2018).","journal-title":"Front. Immunol."},{"key":"2911_CR157","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/cmi.2015.113","volume":"14","author":"D Xu","year":"2017","unstructured":"Xu, D. et al. miR-146a negatively regulates NK cell functions via STAT1 signaling. Cell. Mol. Immunol. 14, 712\u2013720 (2017).","journal-title":"Cell. Mol. Immunol."},{"key":"2911_CR158","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3349\/ymj.2019.60.6.500","volume":"60","author":"Q Yang","year":"2019","unstructured":"Yang, Q. et al. MiR-218-5p suppresses the killing effect of natural killer cell to lung adenocarcinoma by targeting SHMT1. Yonsei Med. J. 60, 500\u2013508 (2019).","journal-title":"Yonsei Med. J."},{"key":"2911_CR159","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1007\/s10620-024-08536-0","volume":"69","author":"CW Tang","year":"2024","unstructured":"Tang, C. W. et al. Regulation of the PD-1\/PD-L1 axis and NK cell dysfunction by exosomal miR-552-5p in gastric cancer. Dig. Dis. Sci. 69, 3276\u20133289 (2024).","journal-title":"Dig. Dis. Sci."},{"key":"2911_CR160","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1182\/blood-2011-12-398099","volume":"119","author":"R Trotta","year":"2012","unstructured":"Trotta, R. et al. miR-155 regulates IFN-gamma production in natural killer cells. Blood. 119, 3478\u20133485 (2012).","journal-title":"Blood."},{"key":"2911_CR161","doi-asserted-by":"publisher","first-page":"5904","DOI":"10.4049\/jimmunol.1301950","volume":"191","author":"RP Sullivan","year":"2013","unstructured":"Sullivan, R. P. et al. MicroRNA-155 tunes both the threshold and extent of NK cell activation via targeting of multiple signaling pathways. J. Immunol. 191, 5904\u20135913 (2013).","journal-title":"J. Immunol."},{"key":"2911_CR162","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/imm.12463","volume":"145","author":"YQ Cheng","year":"2015","unstructured":"Cheng, Y. Q. et al. MicroRNA-155 regulates interferon-gamma production in natural killer cells via Tim-3 signalling in chronic hepatitis C virus infection. Immunology. 145, 485\u2013497 (2015).","journal-title":"Immunology."},{"key":"2911_CR163","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.3324\/haematol.2011.058529","volume":"97","author":"JL Espinoza","year":"2012","unstructured":"Espinoza, J. L. et al. Human microRNA-1245 down-regulates the NKG2D receptor in natural killer cells and impairs NKG2D-mediated functions. Haematologica. 97, 1295\u20131303 (2012).","journal-title":"Haematologica."},{"key":"2911_CR164","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/j.1349-7006.2012.02207.x","volume":"103","author":"J Gong","year":"2012","unstructured":"Gong, J. et al. miR-30c-1* promotes natural killer cell cytotoxicity against human hepatoma cells by targeting the transcription factor HMBOX1. Cancer Sci 103, 645\u2013652 (2012).","journal-title":"Cancer Sci"},{"key":"2911_CR165","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.humimm.2016.04.020","volume":"77","author":"MM Abdelrahman","year":"2016","unstructured":"Abdelrahman, M. M. et al. Enhancing NK cell cytotoxicity by miR-182 in hepatocellular carcinoma. Hum. Immunol. 77, 667\u2013673 (2016).","journal-title":"Hum. Immunol."},{"key":"2911_CR166","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.3389\/fimmu.2018.02360","volume":"9","author":"S Pesce","year":"2018","unstructured":"Pesce, S. et al. New miRNA signature heralds human NK cell subsets at different maturation steps: involvement of miR-146a-5p in the regulation of KIR expression. Front. Immunol. 9, 2360 (2018).","journal-title":"Front. Immunol."},{"key":"2911_CR167","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3390\/genes10080603","volume":"10","author":"R Nutalai","year":"2019","unstructured":"Nutalai, R., Gaudieri, S., Jumnainsong, A. & Leelayuwat, C. Regulation of KIR3DL3 expression via miRNA. Genes (Basel) 10, 603 (2019).","journal-title":"Genes (Basel)"},{"key":"2911_CR168","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1016\/j.apsb.2025.02.034","volume":"15","author":"S Li","year":"2025","unstructured":"Li, S. et al. Identification of a JAK-STAT-miR155HG positive feedback loop in regulating natural killer (NK) cells proliferation and effector functions. Acta Pharm. Sin. B. 15, 1922\u20131937 (2025).","journal-title":"Acta Pharm. Sin. B."},{"key":"2911_CR169","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41577-021-00558-3","volume":"22","author":"NK Bjorkstrom","year":"2022","unstructured":"Bjorkstrom, N. K., Strunz, B. & Ljunggren, H. G. Natural killer cells in antiviral immunity. Nat. Rev. Immunol. 22, 112\u2013123 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"2911_CR170","doi-asserted-by":"publisher","first-page":"1087155","DOI":"10.3389\/fimmu.2023.1087155","volume":"14","author":"P Rascle","year":"2023","unstructured":"Rascle, P. et al. NK cell education: physiological and pathological influences. Front. Immunol. 14, 1087155 (2023).","journal-title":"Front. Immunol."},{"key":"2911_CR171","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.immuni.2020.05.002","volume":"52","author":"N Vabret","year":"2020","unstructured":"Vabret, N. et al. Immunology of COVID-19: current state of the science. Immunity. 52, 910\u2013941 (2020).","journal-title":"Immunity."},{"key":"2911_CR172","doi-asserted-by":"publisher","first-page":"842831","DOI":"10.3389\/fimmu.2022.842831","volume":"13","author":"Y Sun","year":"2022","unstructured":"Sun, Y., Zhou, J. & Jiang, Y. Negative regulation and protective function of natural killer cells in HIV infection: two sides of a coin. Front. Immunol. 13, 842831 (2022).","journal-title":"Front. Immunol."},{"key":"2911_CR173","doi-asserted-by":"publisher","first-page":"842746","DOI":"10.3389\/fimmu.2022.842746","volume":"13","author":"S Duan","year":"2022","unstructured":"Duan, S. & Liu, S. Targeting NK cells for HIV-1 treatment and reservoir clearance. Front. Immunol. 13, 842746 (2022).","journal-title":"Front. Immunol."},{"key":"2911_CR174","doi-asserted-by":"publisher","first-page":"1084109","DOI":"10.3389\/fimmu.2022.1084109","volume":"13","author":"X Jin","year":"2022","unstructured":"Jin, X. & Bi, J. Prospects for NK-based immunotherapy of chronic HBV infection. Front. Immunol. 13, 1084109 (2022).","journal-title":"Front. Immunol."},{"key":"2911_CR175","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/cmi.2014.91","volume":"12","author":"C Sun","year":"2015","unstructured":"Sun, C., Sun, H., Zhang, C. & Tian, Z. NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma. Cell. Mol. Immunol. 12, 292\u2013302 (2015).","journal-title":"Cell. Mol. Immunol."},{"key":"2911_CR176","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1093\/infdis\/jiab216","volume":"224","author":"W Yuan","year":"2021","unstructured":"Yuan, W. et al. Pegylated interferon-a (IFN-a) enhances the inhibitory effect of natural killer cells on regulatory T cells via IFN-gamma in chronic hepatitis B. J. Infect. Dis. 224, 1878\u20131889 (2021).","journal-title":"J. Infect. Dis."},{"key":"2911_CR177","doi-asserted-by":"publisher","first-page":"eabd6832","DOI":"10.1126\/sciimmunol.abd6832","volume":"5","author":"C Maucourant","year":"2020","unstructured":"Maucourant, C. et al. Natural killer cell immunotypes related to COVID-19 disease severity. Sci. Immunol. 5, eabd6832 (2020).","journal-title":"Sci. Immunol."},{"key":"2911_CR178","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1016\/j.cell.2020.10.037","volume":"183","author":"Y Su","year":"2020","unstructured":"Su, Y. et al. Multi-omics resolves a sharp disease-state shift between mild and moderate COVID-19. Cell. 183, 1479\u20131495.e1420 (2020).","journal-title":"Cell."},{"key":"2911_CR179","doi-asserted-by":"publisher","first-page":"4694","DOI":"10.1172\/JCI138554","volume":"130","author":"A Mazzoni","year":"2020","unstructured":"Mazzoni, A. et al. Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent. J. Clin. Invest. 130, 4694\u20134703 (2020).","journal-title":"J. Clin. Invest."},{"key":"2911_CR180","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.smim.2016.05.008","volume":"28","author":"TD Holmes","year":"2016","unstructured":"Holmes, T. D. & Bryceson, Y. T. Natural killer cell memory in context. Semin. Immunol. 28, 368\u2013376 (2016).","journal-title":"Semin. Immunol."},{"key":"2911_CR181","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nri.2015.9","volume":"16","author":"A Cerwenka","year":"2016","unstructured":"Cerwenka, A. & Lanier, L. L. Natural killer cell memory in infection, inflammation and cancer. Nat. Rev. Immunol. 16, 112\u2013123 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"2911_CR182","doi-asserted-by":"publisher","first-page":"830396","DOI":"10.3389\/fimmu.2022.830396","volume":"13","author":"F Gao","year":"2022","unstructured":"Gao, F. et al. Biology and clinical relevance of HCMV-associated adaptive NK cells. Front. Immunol. 13, 830396 (2022).","journal-title":"Front. Immunol."},{"key":"2911_CR183","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.scib.2025.01.002","volume":"70","author":"MH Lin","year":"2025","unstructured":"Lin, M. H. et al. CAR-NK cell therapy: a potential antiviral platform. Sci. Bull. 70, 765\u2013777 (2025).","journal-title":"Sci. Bull."},{"key":"2911_CR184","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1097\/CM9.0000000000001189","volume":"133","author":"H Xia","year":"2020","unstructured":"Xia, H. et al. Safety and efficacy of allogeneic natural killer cell immunotherapy on human immunodeficiency virus type 1 immunological non-responders: a brief report. Chin. Med. J. 133, 2803\u20132807 (2020).","journal-title":"Chin. Med. J."},{"key":"2911_CR185","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30216-8","volume":"13","author":"T Lu","year":"2022","unstructured":"Lu, T. et al. Off-the-shelf CAR natural killer cells secreting IL-15 target spike in treating COVID-19. Nat. Commun. 13, 2576 (2022).","journal-title":"Nat. Commun."},{"key":"2911_CR186","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1021\/acschembio.0c00537","volume":"15","author":"RM Lim","year":"2020","unstructured":"Lim, R. M., Rong, L., Zhen, A. & Xie, J. A universal CAR-NK cell targeting various epitopes of HIV-1 gp160. ACS Chem. Biol. 15, 2299\u20132310 (2020).","journal-title":"ACS Chem. Biol."},{"key":"2911_CR187","doi-asserted-by":"publisher","first-page":"622306","DOI":"10.3389\/fimmu.2021.622306","volume":"12","author":"UC Kucuksezer","year":"2021","unstructured":"Kucuksezer, U. C. et al. The role of natural killer cells in autoimmune diseases. Front. Immunol. 12, 622306 (2021).","journal-title":"Front. Immunol."},{"key":"2911_CR188","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02698-x","volume":"19","author":"X Zhao","year":"2021","unstructured":"Zhao, X. et al. Identification of key biomarkers and immune infiltration in systemic lupus erythematosus by integrated bioinformatics analysis. J. Transl. Med. 19, 35 (2021).","journal-title":"J. Transl. Med."},{"key":"2911_CR189","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/s41590-019-0398-x","volume":"20","author":"A Arazi","year":"2019","unstructured":"Arazi, A. et al. The immune cell landscape in kidneys of patients with lupus nephritis. Nat. Immunol. 20, 902\u2013914 (2019).","journal-title":"Nat. Immunol."},{"key":"2911_CR190","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","volume":"79","author":"J He","year":"2020","unstructured":"He, J. et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 79, 141\u2013149 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"2911_CR191","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s00011-021-01504-8","volume":"70","author":"A Fathollahi","year":"2021","unstructured":"Fathollahi, A. et al. The role of NK cells in rheumatoid arthritis. Inflamm. Res. 70, 1063\u20131073 (2021).","journal-title":"Inflamm. Res."},{"key":"2911_CR192","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-025-08713-9","volume":"641","author":"CA Donado","year":"2025","unstructured":"Donado, C. A. et al. Granzyme K activates the entire complement cascade. Nature. 641, 211\u2013221 (2025).","journal-title":"Nature."},{"key":"2911_CR193","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.3390\/ijms24021526","volume":"24","author":"A Saez","year":"2023","unstructured":"Saez, A. et al. Pathophysiology of inflammatory bowel disease: innate immune system. Int. J. Mol. Sci. 24, 1526 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2911_CR194","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45855-2","volume":"15","author":"S Hu","year":"2024","unstructured":"Hu, S. et al. Mucosal host-microbe interactions associate with clinical phenotypes in inflammatory bowel disease. Nat. Commun. 15, 1470 (2024).","journal-title":"Nat. Commun."},{"key":"2911_CR195","doi-asserted-by":"publisher","first-page":"1130370","DOI":"10.3389\/fimmu.2023.1130370","volume":"14","author":"ME Haugstoyl","year":"2023","unstructured":"Haugstoyl, M. E. et al. Phenotypic diversity of human adipose tissue-resident NK cells in obesity. Front. Immunol. 14, 1130370 (2023).","journal-title":"Front. Immunol."},{"key":"2911_CR196","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1038\/s41366-021-00826-1","volume":"45","author":"DA Mogilenko","year":"2021","unstructured":"Mogilenko, D. A. et al. IFNgamma-producing NK cells in adipose tissue are associated with hyperglycemia and insulin resistance in obese women. Int. J. Obes. 45, 1607\u20131617 (2021).","journal-title":"Int. J. Obes."},{"key":"2911_CR197","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jcmgh.2021.08.019","volume":"13","author":"F Wang","year":"2022","unstructured":"Wang, F. et al. Activated natural killer cell promotes nonalcoholic steatohepatitis through mediating JAK\/STAT pathway. Cell. Mol. Gastroenterol. Hepatol. 13, 257\u2013274 (2022).","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"2911_CR198","doi-asserted-by":"publisher","first-page":"852436","DOI":"10.3389\/fimmu.2022.852436","volume":"13","author":"H Wang","year":"2022","unstructured":"Wang, H. et al. Tim-3 expression causes NK cell dysfunction in type 2 diabetes patients. Front. Immunol. 13, 852436 (2022).","journal-title":"Front. Immunol."},{"key":"2911_CR199","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41577-019-0139-2","volume":"19","author":"KL O\u2019Brien","year":"2019","unstructured":"O\u2019Brien, K. L. & Finlay, D. K. Immunometabolism and natural killer cell responses. Nat. Rev. Immunol. 19, 282\u2013290 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"2911_CR200","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1161\/ATVBAHA.123.320524","volume":"44","author":"AC Bashore","year":"2024","unstructured":"Bashore, A. C. et al. High-dimensional single-cell multimodal landscape of human carotid atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 44, 930\u2013945 (2024).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2911_CR201","doi-asserted-by":"publisher","first-page":"1354617","DOI":"10.3389\/fimmu.2024.1354617","volume":"15","author":"KR Pertiwi","year":"2024","unstructured":"Pertiwi, K. R. et al. Enrichment of type 1 innate lymphoid cells in the course of human atherosclerotic plaque development suggests contribution to atherogenesis. Front. Immunol. 15, 1354617 (2024).","journal-title":"Front. Immunol."},{"key":"2911_CR202","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3389\/fphys.2014.00295","volume":"5","author":"M Knorr","year":"2014","unstructured":"Knorr, M., Munzel, T. & Wenzel, P. Interplay of NK cells and monocytes in vascular inflammation and myocardial infarction. Front. Physiol. 5, 295 (2014).","journal-title":"Front. Physiol."},{"key":"2911_CR203","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.imlet.2015.09.006","volume":"168","author":"I Bonaccorsi","year":"2015","unstructured":"Bonaccorsi, I. et al. Natural killer cells in the innate immunity network of atherosclerosis. Immunol. Lett. 168, 51\u201357 (2015).","journal-title":"Immunol. Lett."},{"key":"2911_CR204","doi-asserted-by":"publisher","first-page":"798155","DOI":"10.3389\/fimmu.2021.798155","volume":"12","author":"MT Palano","year":"2021","unstructured":"Palano, M. T. et al. When a friend becomes your enemy: natural killer cells in atherosclerosis and atherosclerosis-associated risk factors. Front. Immunol. 12, 798155 (2021).","journal-title":"Front. Immunol."},{"key":"2911_CR205","doi-asserted-by":"publisher","first-page":"e042502","DOI":"10.1161\/JAHA.125.042502","volume":"14","author":"RD Patel","year":"2025","unstructured":"Patel, R. D. et al. Associations of immune cell subsets with coronary artery calcium incidence and progression in the multi-ethnic study of atherosclerosis. J. Am. Heart Assoc. 14, e042502 (2025).","journal-title":"J. Am. Heart Assoc."},{"key":"2911_CR206","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12872-021-01857-2","volume":"21","author":"JAC Delaney","year":"2021","unstructured":"Delaney, J. A. C. et al. Natural killer cells, gamma delta T cells and classical monocytes are associated with systolic blood pressure in the multi-ethnic study of atherosclerosis (MESA). BMC Cardiovasc. Disord. 21, 45 (2021).","journal-title":"BMC Cardiovasc. Disord."},{"key":"2911_CR207","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.immuni.2017.11.018","volume":"47","author":"B Fu","year":"2017","unstructured":"Fu, B. et al. Natural killer cells promote fetal development through the secretion of growth-promoting factors. Immunity. 47, 1100\u20131113.e1106 (2017).","journal-title":"Immunity."},{"key":"2911_CR208","doi-asserted-by":"publisher","first-page":"R91","DOI":"10.1530\/REP-14-0271","volume":"149","author":"MT Ratsep","year":"2015","unstructured":"Ratsep, M. T. et al. Uterine natural killer cells: supervisors of vasculature construction in early decidua basalis. Reproduction. 149, R91\u2013R102 (2015).","journal-title":"Reproduction."},{"key":"2911_CR209","doi-asserted-by":"publisher","first-page":"116865","DOI":"10.1016\/j.celrep.2025.116865","volume":"45","author":"H Ino","year":"2026","unstructured":"Ino, H. et al. IL-18 produced by pregnant uterus promotes essential inflammatory responses and fetoplacental growth. Cell Rep 45, 116865 (2026).","journal-title":"Cell Rep"},{"key":"2911_CR210","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1093\/humupd\/dmaa062","volume":"27","author":"I Diaz-Hernandez","year":"2021","unstructured":"Diaz-Hernandez, I., Alecsandru, D., Garcia-Velasco, J. A. & Dominguez, F. Uterine natural killer cells: from foe to friend in reproduction. Hum. Reprod. Update. 27, 720\u2013746 (2021).","journal-title":"Hum. Reprod. Update."},{"key":"2911_CR211","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.540","volume":"11","author":"Y Tao","year":"2021","unstructured":"Tao, Y. et al. Decidual CXCR4(+) CD56(bright) NK cells as a novel NK subset in maternal-foetal immune tolerance to alleviate early pregnancy failure. Clin. Transl. Med. 11, e540 (2021).","journal-title":"Clin. Transl. Med."},{"key":"2911_CR212","doi-asserted-by":"publisher","first-page":"e169836","DOI":"10.1172\/jci.insight.169836","volume":"10","author":"SL Hosking","year":"2024","unstructured":"Hosking, S. L. et al. Treg cells promote decidual vascular remodeling and modulate uterine NK cells in pregnant mice. JCI Insight 10, e169836 (2024).","journal-title":"JCI Insight"},{"key":"2911_CR213","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1093\/humupd\/dmac006","volume":"28","author":"E Von Woon","year":"2022","unstructured":"Von Woon, E. et al. Number and function of uterine natural killer cells in recurrent miscarriage and implantation failure: a systematic review and meta-analysis. Hum. Reprod. Update. 28, 548\u2013582 (2022).","journal-title":"Hum. Reprod. Update."},{"key":"2911_CR214","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.arr.2013.04.003","volume":"12","author":"J Hazeldine","year":"2013","unstructured":"Hazeldine, J. & Lord, J. M. The impact of ageing on natural killer cell function and potential consequences for health in older adults. Ageing Res. Rev. 12, 1069\u20131078 (2013).","journal-title":"Ageing Res. Rev."},{"key":"2911_CR215","doi-asserted-by":"publisher","first-page":"e2309315","DOI":"10.1002\/advs.202309315","volume":"11","author":"S Chen","year":"2024","unstructured":"Chen, S. et al. Dual activity of type III PI3K kinase Vps34 is critical for NK cell development and senescence. Adv. Sci. 11, e2309315 (2024).","journal-title":"Adv. Sci."},{"key":"2911_CR216","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s10522-013-9473-0","volume":"14","author":"A Sagiv","year":"2013","unstructured":"Sagiv, A. & Krizhanovsky, V. Immunosurveillance of senescent cells: the bright side of the senescence program. Biogerontology. 14, 617\u2013628 (2013).","journal-title":"Biogerontology."},{"key":"2911_CR217","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s43587-025-00910-5","volume":"5","author":"J Majewska","year":"2025","unstructured":"Majewska, J. & Krizhanovsky, V. Immune surveillance of senescent cells in aging and disease. Nat. Aging. 5, 1415\u20131424 (2025).","journal-title":"Nat. Aging."},{"key":"2911_CR218","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.ccell.2016.09.003","volume":"30","author":"T Eggert","year":"2016","unstructured":"Eggert, T. et al. Distinct functions of senescence-associated immune responses in liver tumor surveillance and tumor progression. Cancer Cell 30, 533\u2013547 (2016).","journal-title":"Cancer Cell"},{"key":"2911_CR219","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41586-023-05912-0","volume":"616","author":"S Sen Santara","year":"2023","unstructured":"Sen Santara, S. et al. The NK cell receptor NKp46 recognizes ecto-calreticulin on ER-stressed cells. Nature. 616, 348\u2013356 (2023).","journal-title":"Nature."},{"key":"2911_CR220","doi-asserted-by":"publisher","first-page":"0808","DOI":"10.34133\/research.0808","volume":"8","author":"J Wang","year":"2025","unstructured":"Wang, J. et al. Dual roles of SIRT7 inhibition by oroxylin A reprogram HSCs fate: PRMT5 succinylation-driven senescence and ecto-calreticulin-dependent NK cell immune clearance in liver fibrosis. Research. 8, 0808 (2025).","journal-title":"Research."},{"key":"2911_CR221","doi-asserted-by":"publisher","first-page":"eadd1951","DOI":"10.1126\/scitranslmed.add1951","volume":"15","author":"D Yang","year":"2023","unstructured":"Yang, D. et al. NKG2D-CAR T cells eliminate senescent cells in aged mice and nonhuman primates. Sci. Transl. Med. 15, eadd1951 (2023).","journal-title":"Sci. Transl. Med."},{"key":"2911_CR222","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00109-024-02444-6","volume":"102","author":"A Salminen","year":"2024","unstructured":"Salminen, A. The role of the immunosuppressive PD-1\/PD-L1 checkpoint pathway in the aging process and age-related diseases. J. Mol. Med. 102, 733\u2013750 (2024).","journal-title":"J. Mol. Med."},{"key":"2911_CR223","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.tcb.2024.06.007","volume":"35","author":"TW Wang","year":"2025","unstructured":"Wang, T. W. & Nakanishi, M. Immune surveillance of senescence: potential application to age-related diseases. Trends Cell Biol 35, 248\u2013257 (2025).","journal-title":"Trends Cell Biol"},{"key":"2911_CR224","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s43587-024-00776-z","volume":"5","author":"C Iltis","year":"2025","unstructured":"Iltis, C. et al. A ganglioside-based immune checkpoint enables senescent cells to evade immunosurveillance during aging. Nat. Aging. 5, 219\u2013236 (2025).","journal-title":"Nat. Aging."},{"key":"2911_CR225","doi-asserted-by":"publisher","first-page":"eadn2811","DOI":"10.1126\/sciadv.adn2811","volume":"11","author":"V Reen","year":"2025","unstructured":"Reen, V. et al. SMARCA4 regulates the NK-mediated killing of senescent cells. Sci. Adv. 11, eadn2811 (2025).","journal-title":"Sci. Adv."},{"key":"2911_CR226","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41420-024-01976-7","volume":"10","author":"Y Deng","year":"2024","unstructured":"Deng, Y. et al. Targeting senescent cells with NKG2D-CAR T cells. Cell Death Discov 10, 217 (2024).","journal-title":"Cell Death Discov"},{"key":"2911_CR227","doi-asserted-by":"publisher","first-page":"e73849","DOI":"10.7554\/eLife.73849","volume":"11","author":"S Rodriguez-Lorenzo","year":"2022","unstructured":"Rodriguez-Lorenzo, S. et al. Single-cell profiling reveals periventricular CD56bright NK cell accumulation in multiple sclerosis. Elife 11, e73849 (2022).","journal-title":"Elife"},{"key":"2911_CR228","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-022-02667-9","volume":"19","author":"F Straeten","year":"2022","unstructured":"Straeten, F. et al. Integrated single-cell transcriptomics of cerebrospinal fluid cells in treatment-naive multiple sclerosis. J. Neuroinflammation. 19, 306 (2022).","journal-title":"J. Neuroinflammation."},{"key":"2911_CR229","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12979-024-00445-0","volume":"21","author":"Q Zhang","year":"2024","unstructured":"Zhang, Q. et al. Neuroinflammation in Alzheimer\u2019s disease: insights from peripheral immune cells. Immun. Ageing. 21, 38 (2024).","journal-title":"Immun. Ageing."},{"key":"2911_CR230","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13195-025-01681-2","volume":"17","author":"CH Zuniga","year":"2025","unstructured":"Zuniga, C. H. et al. Treatment of Alzheimer\u2019s disease subjects with expanded non-genetically modified autologous natural killer cells (SNK01): a phase I study. Alzheimers Res. Ther. 17, 40 (2025).","journal-title":"Alzheimers Res. Ther."},{"key":"2911_CR231","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1126\/science.aad2035","volume":"352","author":"LK Mackay","year":"2016","unstructured":"Mackay, L. K. et al. Hobit and Blimp1 instruct a universal transcriptional program of tissue residency in lymphocytes. Science. 352, 459\u2013463 (2016).","journal-title":"Science."},{"key":"2911_CR232","doi-asserted-by":"publisher","first-page":"e20240930","DOI":"10.1084\/jem.20240930","volume":"222","author":"C Sparano","year":"2025","unstructured":"Sparano, C. et al. Autocrine TGF-\u03b21 drives tissue-specific differentiation and function of resident NK cells. J. Exp. Med. 222, e20240930 (2025).","journal-title":"J. Exp. Med."},{"key":"2911_CR233","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1002\/eji.201646559","volume":"46","author":"C Harmon","year":"2016","unstructured":"Harmon, C. et al. Tissue-resident Eomes(hi) T-bet(lo) CD56(bright) NK cells with reduced proinflammatory potential are enriched in the adult human liver. Eur. J. Immunol. 46, 2111\u20132120 (2016).","journal-title":"Eur. J. Immunol."},{"key":"2911_CR234","doi-asserted-by":"publisher","first-page":"107855","DOI":"10.1016\/j.celrep.2020.107855","volume":"32","author":"G Dodard","year":"2020","unstructured":"Dodard, G. et al. Inflammation-induced lactate leads to rapid loss of hepatic tissue-resident NK cells. Cell Rep 32, 107855 (2020).","journal-title":"Cell Rep"},{"key":"2911_CR235","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1038\/s41423-021-00739-z","volume":"18","author":"F Wang","year":"2021","unstructured":"Wang, F., Qualls, A. E., Marques-Fernandez, L. & Colucci, F. Biology and pathology of the uterine microenvironment and its natural killer cells. Cell. Mol. Immunol. 18, 2101\u20132113 (2021).","journal-title":"Cell. Mol. Immunol."},{"key":"2911_CR236","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1038\/s41416-023-02321-y","volume":"129","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. The prognostic and biology of tumour-infiltrating lymphocytes in the immunotherapy of cancer. Br. J. Cancer. 129, 1041\u20131049 (2023).","journal-title":"Br. J. Cancer."},{"key":"2911_CR237","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01737-7","volume":"22","author":"Y Zhou","year":"2023","unstructured":"Zhou, Y., Cheng, L., Liu, L. & Li, X. NK cells are never alone: crosstalk and communication in tumour microenvironments. Mol. Cancer. 22, 34 (2023).","journal-title":"Mol. Cancer."},{"key":"2911_CR238","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.1073\/pnas.0730640100","volume":"100","author":"R Castriconi","year":"2003","unstructured":"Castriconi, R. et al. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc. Natl. Acad. Sci. USA. 100, 4120\u20134125 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"2911_CR239","doi-asserted-by":"publisher","first-page":"ra19","DOI":"10.1126\/scisignal.aad1884","volume":"9","author":"S Viel","year":"2016","unstructured":"Viel, S. et al. TGF-beta inhibits the activation and functions of NK cells by repressing the mTOR pathway. Sci. Signal. 9, ra19 (2016).","journal-title":"Sci. Signal."},{"key":"2911_CR240","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/ni.3800","volume":"18","author":"Y Gao","year":"2017","unstructured":"Gao, Y. et al. Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells. Nat. Immunol. 18, 1004\u20131015 (2017).","journal-title":"Nat. Immunol."},{"key":"2911_CR241","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.immuni.2020.11.018","volume":"53","author":"NH Knudsen","year":"2020","unstructured":"Knudsen, N. H. & Manguso, R. T. Tumor-derived PGE2 gives NK cells a headache. Immunity. 53, 1131\u20131132 (2020).","journal-title":"Immunity."},{"key":"2911_CR242","doi-asserted-by":"publisher","first-page":"e2350635","DOI":"10.1002\/eji.202350635","volume":"54","author":"C Patterson","year":"2024","unstructured":"Patterson, C., Hazime, K. S., Zelenay, S. & Davis, D. M. Prostaglandin E(2) impacts multiple stages of the natural killer cell antitumor immune response. Eur. J. Immunol. 54, e2350635 (2024).","journal-title":"Eur. J. Immunol."},{"key":"2911_CR243","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ccell.2023.01.001","volume":"41","author":"X Liu","year":"2023","unstructured":"Liu, X. et al. Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance. Cancer Cell 41, 272\u2013287.e279 (2023).","journal-title":"Cancer Cell"},{"key":"2911_CR244","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.ccell.2022.08.005","volume":"40","author":"B Salome","year":"2022","unstructured":"Salome, B. et al. NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer. Cancer Cell 40, 1027\u20131043.e1029 (2022).","journal-title":"Cancer Cell"},{"key":"2911_CR245","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","volume":"175","author":"P Andre","year":"2018","unstructured":"Andre, P. et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell. 175, 1731\u20131743.e1713 (2018).","journal-title":"Cell."},{"key":"2911_CR246","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1158\/1078-0432.CCR-25-0447","volume":"32","author":"M Lopez-Botet","year":"2026","unstructured":"Lopez-Botet, M., Vilches, C. & Muntasell, A. The CD94\/NKG2A-HLA-E axis as a target in cancer immunotherapy: a critical perspective. Clin. Cancer Res. 32, 1013\u20131019 (2026).","journal-title":"Clin. Cancer Res."},{"key":"2911_CR247","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01744-8","volume":"22","author":"Z Yuan","year":"2023","unstructured":"Yuan, Z. et al. Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments. Mol. Cancer. 22, 48 (2023).","journal-title":"Mol. Cancer."},{"key":"2911_CR248","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06697-4","volume":"15","author":"Z Mai","year":"2024","unstructured":"Mai, Z. et al. Modulating extracellular matrix stiffness: a strategic approach to boost cancer immunotherapy. Cell Death Dis 15, 307 (2024).","journal-title":"Cell Death Dis"},{"key":"2911_CR249","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1002\/cac2.12294","volume":"42","author":"H Zhou","year":"2022","unstructured":"Zhou, H. et al. Functions and clinical significance of mechanical tumor microenvironment: cancer cell sensing, mechanobiology and metastasis. Cancer Commun 42, 374\u2013400 (2022).","journal-title":"Cancer Commun"},{"key":"2911_CR250","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/nature01112","volume":"419","author":"V Groh","year":"2002","unstructured":"Groh, V., Wu, J., Yee, C. & Spies, T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 419, 734\u2013738 (2002).","journal-title":"Nature."},{"key":"2911_CR251","doi-asserted-by":"publisher","first-page":"3448","DOI":"10.2741\/2939","volume":"13","author":"HR Salih","year":"2008","unstructured":"Salih, H. R., Holdenrieder, S. & Steinle, A. Soluble NKG2D ligands: prevalence, release, and functional impact. Front. Biosci. 13, 3448\u20133456 (2008).","journal-title":"Front. Biosci."},{"key":"2911_CR252","doi-asserted-by":"publisher","first-page":"11808","DOI":"10.1073\/pnas.1804931115","volume":"115","author":"L Shi","year":"2018","unstructured":"Shi, L. et al. Modulation of NKG2D, NKp46, and Ly49C\/I facilitates natural killer cell-mediated control of lung cancer. Proc. Natl. Acad. Sci. USA. 115, 11808\u201311813 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"2911_CR253","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01222-5","volume":"19","author":"PF Zhang","year":"2020","unstructured":"Zhang, P. F. et al. Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma. Mol. Cancer. 19, 110 (2020).","journal-title":"Mol. Cancer."},{"key":"2911_CR254","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41590-018-0132-0","volume":"19","author":"Q Zhang","year":"2018","unstructured":"Zhang, Q. et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat. Immunol. 19, 723\u2013732 (2018).","journal-title":"Nat. Immunol."},{"key":"2911_CR255","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15776","volume":"8","author":"H Seo","year":"2017","unstructured":"Seo, H. et al. IL-21-mediated reversal of NK cell exhaustion facilitates anti-tumour immunity in MHC class I-deficient tumours. Nat. Commun. 8, 15776 (2017).","journal-title":"Nat. Commun."},{"key":"2911_CR256","doi-asserted-by":"publisher","first-page":"7452","DOI":"10.4049\/jimmunol.1002629","volume":"185","author":"EM de Kruijf","year":"2010","unstructured":"de Kruijf, E. M. et al. HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients. J. Immunol. 185, 7452\u20137459 (2010).","journal-title":"J. Immunol."},{"key":"2911_CR257","doi-asserted-by":"publisher","first-page":"e2505658122","DOI":"10.1073\/pnas.2505658122","volume":"122","author":"Y Zhang","year":"2025","unstructured":"Zhang, Y. et al. A PSAT1 buff of YBX1 transcriptionally sustains HLA-E-mediated evasion of NK immunity. Proc. Natl. Acad. Sci. USA. 122, e2505658122 (2025).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"2911_CR258","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-44789-z","volume":"15","author":"I Dean","year":"2024","unstructured":"Dean, I. et al. Rapid functional impairment of natural killer cells following tumor entry limits anti-tumor immunity. Nat. Commun. 15, 683 (2024).","journal-title":"Nat. Commun."},{"key":"2911_CR259","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1038\/s41590-019-0511-1","volume":"20","author":"X Zheng","year":"2019","unstructured":"Zheng, X. et al. Mitochondrial fragmentation limits NK cell-based tumor immunosurveillance. Nat. Immunol. 20, 1656\u20131667 (2019).","journal-title":"Nat. Immunol."},{"key":"2911_CR260","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.cmet.2021.03.023","volume":"33","author":"SM Poznanski","year":"2021","unstructured":"Poznanski, S. M. et al. Metabolic flexibility determines human NK cell functional fate in the tumor microenvironment. Cell Metab 33, 1205\u20131220.e1205 (2021).","journal-title":"Cell Metab"},{"key":"2911_CR261","doi-asserted-by":"publisher","first-page":"e002044","DOI":"10.1136\/jitc-2020-002044","volume":"9","author":"K Slattery","year":"2021","unstructured":"Slattery, K. et al. TGF\u03b2 drives NK cell metabolic dysfunction in human metastatic breast cancer. J. Immunother. Cancer 9, e002044 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"2911_CR262","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41573-024-01098-w","volume":"24","author":"S Viel","year":"2025","unstructured":"Viel, S., Vivier, E., Walzer, T. & Marcais, A. Targeting metabolic dysfunction of CD8 T cells and natural killer cells in cancer. Nat. Rev. Drug Discov. 24, 190\u2013208 (2025).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2911_CR263","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/ni.2936","volume":"15","author":"A Marcais","year":"2014","unstructured":"Marcais, A. et al. The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells. Nat. Immunol. 15, 749\u2013757 (2014).","journal-title":"Nat. Immunol."},{"key":"2911_CR264","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04719-2","volume":"9","author":"RM Loftus","year":"2018","unstructured":"Loftus, R. M. et al. Amino acid-dependent cMyc expression is essential for NK cell metabolic and functional responses in mice. Nat. Commun. 9, 2341 (2018).","journal-title":"Nat. Commun."},{"key":"2911_CR265","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13046-023-02629-w","volume":"42","author":"JX Cui","year":"2023","unstructured":"Cui, J. X. et al. L-kynurenine induces NK cell loss in gastric cancer microenvironment via promoting ferroptosis. J. Exp. Clin. Cancer Res. 42, 52 (2023).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2911_CR266","doi-asserted-by":"publisher","first-page":"109210","DOI":"10.1016\/j.celrep.2021.109210","volume":"35","author":"S Sheppard","year":"2021","unstructured":"Sheppard, S. et al. Lactate dehydrogenase A-dependent aerobic glycolysis promotes natural killer cell anti-viral and anti-tumor function. Cell Rep 35, 109210 (2021).","journal-title":"Cell Rep"},{"key":"2911_CR267","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cmet.2016.08.011","volume":"24","author":"A Brand","year":"2016","unstructured":"Brand, A. et al. LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metab 24, 657\u2013671 (2016).","journal-title":"Cell Metab"},{"key":"2911_CR268","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1158\/2326-6066.CIR-18-0481","volume":"7","author":"C Harmon","year":"2019","unstructured":"Harmon, C. et al. Lactate-mediated acidification of tumor microenvironment induces apoptosis of liver-resident NK cells in colorectal liver metastasis. Cancer Immunol. Res. 7, 335\u2013346 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"2911_CR269","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41586-020-03045-2","volume":"591","author":"MJ Watson","year":"2021","unstructured":"Watson, M. J. et al. Metabolic support of tumour-infiltrating regulatory T cells by lactic acid. Nature. 591, 645\u2013651 (2021).","journal-title":"Nature."},{"key":"2911_CR270","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42734-0","volume":"14","author":"KL Todd","year":"2023","unstructured":"Todd, K. L. et al. A(2A)R eGFP reporter mouse enables elucidation of A(2A)R expression dynamics during anti-tumor immune responses. Nat. Commun. 14, 6990 (2023).","journal-title":"Nat. Commun."},{"key":"2911_CR271","doi-asserted-by":"publisher","first-page":"189005","DOI":"10.1016\/j.bbcan.2023.189005","volume":"1878","author":"C Zhang","year":"2023","unstructured":"Zhang, C., Wang, K. & Wang, H. Adenosine in cancer immunotherapy: taking off on a new plane. Biochim Biophys. Acta Rev. Cancer. 1878, 189005 (2023).","journal-title":"Biochim Biophys. Acta Rev. Cancer."},{"key":"2911_CR272","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1158\/0008-5472.CAN-17-2826","volume":"78","author":"A Young","year":"2018","unstructured":"Young, A. et al. A2AR adenosine signaling suppresses natural killer cell maturation in the tumor microenvironment. Cancer Res 78, 1003\u20131016 (2018).","journal-title":"Cancer Res"},{"key":"2911_CR273","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1182\/blood.2024025706","volume":"145","author":"C Rothfuss","year":"2025","unstructured":"Rothfuss, C. et al. Two-layered immune escape in AML is overcome by Fcgamma receptor activation and inhibition of PGE2 signaling in NK cells. Blood 145, 1395\u20131406 (2025).","journal-title":"Blood"},{"key":"2911_CR274","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.immuni.2020.05.001","volume":"52","author":"J Ni","year":"2020","unstructured":"Ni, J. et al. Single-cell RNA sequencing of tumor-infiltrating NK cells reveals that inhibition of transcription factor HIF-1alpha unleashes NK cell activity. Immunity. 52, 1075\u20131087.e1078 (2020).","journal-title":"Immunity."},{"key":"2911_CR275","doi-asserted-by":"publisher","first-page":"eabh4050","DOI":"10.1126\/sciadv.abh4050","volume":"8","author":"T Walle","year":"2022","unstructured":"Walle, T. et al. Radiotherapy orchestrates natural killer cell dependent antitumor immune responses through CXCL8. Sci. Adv. 8, eabh4050 (2022).","journal-title":"Sci. Adv."},{"key":"2911_CR276","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s00018-024-05290-4","volume":"81","author":"GY Lian","year":"2024","unstructured":"Lian, G. Y. et al. Disrupting Smad3 potentiates immunostimulatory function of NK cells against lung carcinoma by promoting GM-CSF production. Cell. Mol. Life Sci. 81, 262 (2024).","journal-title":"Cell. Mol. Life Sci."},{"key":"2911_CR277","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-017-0664-4","volume":"37","author":"Z Yang","year":"2018","unstructured":"Yang, Z. et al. Notch1 signaling in melanoma cells promoted tumor-induced immunosuppression via upregulation of TGF-beta1. J. Exp. Clin. Cancer Res. 37, 1 (2018).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2911_CR278","doi-asserted-by":"publisher","first-page":"eadi2952","DOI":"10.1126\/scitranslmed.adi2952","volume":"16","author":"SY Neo","year":"2024","unstructured":"Neo, S. Y. et al. Tumor-associated NK cells drive MDSC-mediated tumor immune tolerance through the IL-6\/STAT3 axis. Sci. Transl. Med. 16, eadi2952 (2024).","journal-title":"Sci. Transl. Med."},{"key":"2911_CR279","doi-asserted-by":"publisher","first-page":"e006130","DOI":"10.1136\/jitc-2022-006130","volume":"11","author":"YE Lee","year":"2023","unstructured":"Lee, Y. E. et al. Synergistic therapeutic combination with a CAF inhibitor enhances CAR-NK-mediated cytotoxicity via reduction of CAF-released IL-6. J. Immunother. Cancer 11, e006130 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"2911_CR280","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1158\/2159-8290.CD-24-1232","volume":"15","author":"NJ Song","year":"2025","unstructured":"Song, N. J. et al. Tumor-associated NK cells regulate distinct CD8+ T-cell differentiation program in cancer and contribute to resistance against immune checkpoint blockers. Cancer Discov 15, 1835\u20131857 (2025).","journal-title":"Cancer Discov"},{"key":"2911_CR281","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1158\/2159-8290.CD-24-1208","volume":"15","author":"J Pozniak","year":"2025","unstructured":"Pozniak, J. et al. Cytotoxic NK cells impede response to checkpoint immunotherapy in melanoma with an immune-excluded phenotype. Cancer Discov 15, 1819\u20131834 (2025).","journal-title":"Cancer Discov"},{"key":"2911_CR282","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1593\/neo.121758","volume":"15","author":"A Bruno","year":"2013","unstructured":"Bruno, A. et al. The proangiogenic phenotype of natural killer cells in patients with non-small cell lung cancer. Neoplasia. 15, 133\u2013142 (2013).","journal-title":"Neoplasia."},{"key":"2911_CR283","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06976-0","volume":"15","author":"L Coenon","year":"2024","unstructured":"Coenon, L. et al. Natural Killer cells at the frontline in the fight against cancer. Cell Death Dis 15, 614 (2024).","journal-title":"Cell Death Dis"},{"key":"2911_CR284","doi-asserted-by":"crossref","unstructured":"Russick, J. et al. Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions. J. Immunother. Cancer 8, (2020).","DOI":"10.1136\/jitc-2020-001054"},{"key":"2911_CR285","doi-asserted-by":"publisher","first-page":"953","DOI":"10.4049\/jimmunol.1502291","volume":"197","author":"XL Iraolagoitia","year":"2016","unstructured":"Iraolagoitia, X. L. et al. NK cells restrain spontaneous antitumor CD8+ T cell priming through PD-1\/PD-L1 interactions with dendritic cells. J. Immunol. 197, 953\u2013961 (2016).","journal-title":"J. Immunol."},{"key":"2911_CR286","doi-asserted-by":"publisher","first-page":"18360","DOI":"10.1073\/pnas.1110584108","volume":"108","author":"M Nakayama","year":"2011","unstructured":"Nakayama, M. et al. Natural killer (NK)-dendritic cell interactions generate MHC class II-dressed NK cells that regulate CD4+ T cells. Proc. Natl. Acad. Sci. USA. 108, 18360\u201318365 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"2911_CR287","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.canlet.2015.09.017","volume":"369","author":"Z Zhou","year":"2015","unstructured":"Zhou, Z. et al. TLR7\/8 agonists promote NK-DC cross-talk to enhance NK cell anti-tumor effects in hepatocellular carcinoma. Cancer Lett 369, 298\u2013306 (2015).","journal-title":"Cancer Lett"},{"key":"2911_CR288","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1172\/JCI125916","volume":"129","author":"A Merino","year":"2019","unstructured":"Merino, A. et al. Chronic stimulation drives human NK cell dysfunction and epigenetic reprograming. J. Clin. Invest. 129, 3770\u20133785 (2019).","journal-title":"J. Clin. Invest."},{"key":"2911_CR289","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1038\/s41375-023-01972-3","volume":"37","author":"A Palau","year":"2023","unstructured":"Palau, A. et al. Perturbed epigenetic transcriptional regulation in AML with IDH mutations causes increased susceptibility to NK cells. Leukemia. 37, 1830\u20131841 (2023).","journal-title":"Leukemia."},{"key":"2911_CR290","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1093\/neuonc\/now061","volume":"18","author":"X Zhang","year":"2016","unstructured":"Zhang, X. et al. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression. Neuro Oncol 18, 1402\u20131412 (2016).","journal-title":"Neuro Oncol"},{"key":"2911_CR291","doi-asserted-by":"publisher","first-page":"e006238","DOI":"10.1136\/jitc-2022-006238","volume":"11","author":"Y Morimoto","year":"2023","unstructured":"Morimoto, Y. et al. MUC1-C is a master regulator of MICA\/B NKG2D ligand and exosome secretion in human cancer cells. J. Immunother. Cancer 11, e006238 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"2911_CR292","doi-asserted-by":"publisher","first-page":"E3509","DOI":"10.1073\/pnas.1802691115","volume":"115","author":"S Bugide","year":"2018","unstructured":"Bugide, S., Green, M. R. & Wajapeyee, N. Inhibition of Enhancer of zeste homolog 2 (EZH2) induces natural killer cell-mediated eradication of hepatocellular carcinoma cells. Proc. Natl. Acad. Sci. USA. 115, E3509\u2013E3518 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"2911_CR293","doi-asserted-by":"publisher","first-page":"e2102718118","DOI":"10.1073\/pnas.2102718118","volume":"118","author":"S Bugide","year":"2021","unstructured":"Bugide, S., Gupta, R., Green, M. R. & Wajapeyee, N. EZH2 inhibits NK cell-mediated antitumor immunity by suppressing CXCL10 expression in an HDAC10-dependent manner. Proc. Natl. Acad. Sci. USA 118, e2102718118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2911_CR294","doi-asserted-by":"publisher","first-page":"114333","DOI":"10.1016\/j.celrep.2024.114333","volume":"43","author":"H Sudholz","year":"2024","unstructured":"Sudholz, H. et al. DOT1L maintains NK cell phenotype and function for optimal tumor control. Cell Rep 43, 114333 (2024).","journal-title":"Cell Rep"},{"key":"2911_CR295","doi-asserted-by":"publisher","first-page":"e55681","DOI":"10.15252\/embr.202255681","volume":"24","author":"SM Kim","year":"2023","unstructured":"Kim, S. M. et al. FTO negatively regulates the cytotoxic activity of natural killer cells. EMBO Rep 24, e55681 (2023).","journal-title":"EMBO Rep"},{"key":"2911_CR296","doi-asserted-by":"publisher","first-page":"1440308","DOI":"10.3389\/fimmu.2024.1440308","volume":"15","author":"X Li","year":"2024","unstructured":"Li, X., Wang, Y., Cai, L. & Huang, S. SMAD4 enhances the cytotoxic efficacy of human NK cells against colorectal cancer cells via the m(6)A reader YTHDF2. Front. Immunol. 15, 1440308 (2024).","journal-title":"Front. Immunol."},{"key":"2911_CR297","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06791-7","volume":"15","author":"AS Pathania","year":"2024","unstructured":"Pathania, A. S. et al. The miR-29 family facilitates the activation of NK-cell immune responses by targeting the B7-H3 immune checkpoint in neuroblastoma. Cell Death Dis 15, 428 (2024).","journal-title":"Cell Death Dis"},{"key":"2911_CR298","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01185-0","volume":"9","author":"Q Jiang","year":"2025","unstructured":"Jiang, Q. et al. Exosomal SNHG26 mediates immunosuppression by impairing NK cells in tongue cancer. NPJ Precis. Oncol. 9, 402 (2025).","journal-title":"NPJ Precis. Oncol."},{"key":"2911_CR299","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1038\/s44318-024-00094-5","volume":"43","author":"B Sabag","year":"2024","unstructured":"Sabag, B. et al. Dysfunctional natural killer cells can be reprogrammed to regain anti-tumor activity. EMBO J 43, 2552\u20132581 (2024).","journal-title":"EMBO J"},{"key":"2911_CR300","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10258","volume":"7","author":"H Ohguchi","year":"2016","unstructured":"Ohguchi, H. et al. The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival. Nat. Commun. 7, 10258 (2016).","journal-title":"Nat. Commun."},{"key":"2911_CR301","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/s41556-024-01472-1","volume":"26","author":"Y Gruper","year":"2024","unstructured":"Gruper, Y., Ben-Shmuel, A. & Scherz-Shouval, R. HSF1 renders NK cells too stressed to respond. Nat. Cell Biol. 26, 1630\u20131631 (2024).","journal-title":"Nat. Cell Biol."},{"key":"2911_CR302","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.1172\/JCI121227","volume":"128","author":"Y Wang","year":"2018","unstructured":"Wang, Y. et al. SMAD4 promotes TGF-beta-independent NK cell homeostasis and maturation and antitumor immunity. J. Clin. Invest. 128, 5123\u20135136 (2018).","journal-title":"J. Clin. Invest."},{"key":"2911_CR303","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/ni.3809","volume":"18","author":"VS Cortez","year":"2017","unstructured":"Cortez, V. S. et al. SMAD4 impedes the conversion of NK cells into ILC1-like cells by curtailing non-canonical TGF-beta signaling. Nat. Immunol. 18, 995\u20131003 (2017).","journal-title":"Nat. Immunol."},{"key":"2911_CR304","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1038\/s41590-024-01884-z","volume":"25","author":"H Netskar","year":"2024","unstructured":"Netskar, H. et al. Pan-cancer profiling of tumor-infiltrating natural killer cells through transcriptional reference mapping. Nat. Immunol. 25, 1445\u20131459 (2024).","journal-title":"Nat. Immunol."},{"key":"2911_CR305","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1016\/j.cell.2023.07.036","volume":"186","author":"J Massague","year":"2023","unstructured":"Massague, J. & Sheppard, D. TGF-beta signaling in health and disease. Cell. 186, 4007\u20134037 (2023).","journal-title":"Cell."},{"key":"2911_CR306","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41423-025-01297-4","volume":"22","author":"Z Shen","year":"2025","unstructured":"Shen, Z. et al. Adjusting the scope of natural killer cells in cancer therapy. Cell. Mol. Immunol. 22, 699\u2013711 (2025).","journal-title":"Cell. Mol. Immunol."},{"key":"2911_CR307","doi-asserted-by":"publisher","first-page":"104870","DOI":"10.1016\/j.critrevonc.2025.104870","volume":"215","author":"X Wu","year":"2025","unstructured":"Wu, X. & Matosevic, S. Pathology, immunosuppression and NK cell immunotherapy of non-small cell lung cancer. Crit. Rev. Oncol. Hematol. 215, 104870 (2025).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"2911_CR308","doi-asserted-by":"publisher","first-page":"100930","DOI":"10.1016\/j.tranon.2020.100930","volume":"14","author":"S Nersesian","year":"2021","unstructured":"Nersesian, S. et al. NK cell infiltration is associated with improved overall survival in solid cancers: A systematic review and meta-analysis. Transl. Oncol. 14, 100930 (2021).","journal-title":"Transl. Oncol."},{"key":"2911_CR309","doi-asserted-by":"publisher","first-page":"100074","DOI":"10.1016\/j.crimmu.2023.100074","volume":"5","author":"N Heldager Pedersen","year":"2024","unstructured":"Heldager Pedersen, N. et al. An increase in regulatory T cells in peripheral blood correlates with an adverse prognosis for malignant melanoma patients\u2014a study of T cells and natural killer cells. Curr. Res. Immunol. 5, 100074 (2024).","journal-title":"Curr. Res. Immunol."},{"key":"2911_CR310","doi-asserted-by":"publisher","first-page":"1474652","DOI":"10.3389\/fimmu.2024.1474652","volume":"15","author":"M Khan","year":"2024","unstructured":"Khan, M. et al. Transcriptional signature of CD56(bright) NK cells predicts favourable prognosis in bladder cancer. Front. Immunol. 15, 1474652 (2024).","journal-title":"Front. Immunol."},{"key":"2911_CR311","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1158\/0008-5472.CAN-10-4179","volume":"71","author":"S Platonova","year":"2011","unstructured":"Platonova, S. et al. Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res 71, 5412\u20135422 (2011).","journal-title":"Cancer Res"},{"key":"2911_CR312","doi-asserted-by":"publisher","first-page":"e1264562","DOI":"10.1080\/2162402X.2016.1264562","volume":"6","author":"C Sun","year":"2017","unstructured":"Sun, C. et al. High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer. Oncoimmunology. 6, e1264562 (2017).","journal-title":"Oncoimmunology."},{"key":"2911_CR313","doi-asserted-by":"publisher","first-page":"1942673","DOI":"10.1080\/2162402X.2021.1942673","volume":"10","author":"L Yu","year":"2021","unstructured":"Yu, L. et al. TIGIT(+) TIM-3(+) NK cells are correlated with NK cell exhaustion and disease progression in patients with hepatitis B virus-related hepatocellular carcinoma. Oncoimmunology. 10, 1942673 (2021).","journal-title":"Oncoimmunology."},{"key":"2911_CR314","doi-asserted-by":"publisher","first-page":"760","DOI":"10.3389\/fimmu.2017.00760","volume":"8","author":"J Bi","year":"2017","unstructured":"Bi, J. & Tian, Z. NK cell exhaustion. Front. Immunol. 8, 760 (2017).","journal-title":"Front. Immunol."},{"key":"2911_CR315","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/imm.13464","volume":"166","author":"K Roe","year":"2022","unstructured":"Roe, K. NK-cell exhaustion, B-cell exhaustion and T-cell exhaustion-the differences and similarities. Immunology. 166, 155\u2013168 (2022).","journal-title":"Immunology."},{"key":"2911_CR316","doi-asserted-by":"publisher","first-page":"e96219","DOI":"10.1172\/jci.insight.96219","volume":"3","author":"M Felices","year":"2018","unstructured":"Felices, M. et al. Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect. JCI Insight 3, e96219 (2018).","journal-title":"JCI Insight"},{"key":"2911_CR317","doi-asserted-by":"publisher","first-page":"1018685","DOI":"10.3389\/fimmu.2022.1018685","volume":"13","author":"H Chi","year":"2022","unstructured":"Chi, H. et al. Natural killer cell-related prognosis signature characterizes immune landscape and predicts prognosis of HNSCC. Front. Immunol. 13, 1018685 (2022).","journal-title":"Front. Immunol."},{"key":"2911_CR318","doi-asserted-by":"publisher","first-page":"1200282","DOI":"10.3389\/fimmu.2023.1200282","volume":"14","author":"Z Liu","year":"2023","unstructured":"Liu, Z. et al. Natural killer cell-related prognostic risk model predicts prognosis and treatment outcomes in triple-negative breast cancer. Front. Immunol. 14, 1200282 (2023).","journal-title":"Front. Immunol."},{"key":"2911_CR319","doi-asserted-by":"publisher","first-page":"6287","DOI":"10.1158\/1078-0432.CCR-11-1347","volume":"17","author":"MR Parkhurst","year":"2011","unstructured":"Parkhurst, M. R., Riley, J. P., Dudley, M. E. & Rosenberg, S. A. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin. Cancer Res. 17, 6287\u20136297 (2011).","journal-title":"Clin. Cancer Res."},{"key":"2911_CR320","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","volume":"18","author":"JA Myers","year":"2021","unstructured":"Myers, J. A. & Miller, J. S. Exploring the NK cell platform for cancer immunotherapy. Nat. Rev. Clin. Oncol. 18, 85\u2013100 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2911_CR321","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1182\/blood.2022016200","volume":"141","author":"MM Berrien-Elliott","year":"2023","unstructured":"Berrien-Elliott, M. M., Jacobs, M. T. & Fehniger, T. A. Allogeneic natural killer cell therapy. Blood. 141, 856\u2013868 (2023).","journal-title":"Blood."},{"key":"2911_CR322","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jcyt.2022.12.003","volume":"25","author":"H Klingemann","year":"2023","unstructured":"Klingemann, H. The NK-92 cell line-30 years later: its impact on natural killer cell research and treatment of cancer. Cytotherapy. 25, 451\u2013457 (2023).","journal-title":"Cytotherapy."},{"key":"2911_CR323","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1093\/neuonc\/noad087","volume":"25","author":"MC Burger","year":"2023","unstructured":"Burger, M. C. et al. Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma. Neuro Oncol 25, 2058\u20132071 (2023).","journal-title":"Neuro Oncol"},{"key":"2911_CR324","doi-asserted-by":"publisher","first-page":"e000450","DOI":"10.1136\/jitc-2019-000450","volume":"8","author":"KP Fabian","year":"2020","unstructured":"Fabian, K. P. et al. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations. J. Immunother. Cancer 8, e000450 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"2911_CR325","doi-asserted-by":"publisher","first-page":"e013714","DOI":"10.1136\/jitc-2025-013714","volume":"14","author":"N Wang","year":"2026","unstructured":"Wang, N. et al. Donor-derived CD19-targeted CAR-NK cells induce complete remission in a child with relapsed B-ALL after failure of blinatumomab and autologous CD19-targeted CAR-T. J. Immunother. Cancer 14, e013714 (2026).","journal-title":"J. Immunother. Cancer"},{"key":"2911_CR326","doi-asserted-by":"publisher","first-page":"eadk4893","DOI":"10.1126\/sciimmunol.adk4893","volume":"9","author":"JA Foltz","year":"2024","unstructured":"Foltz, J. A. et al. Cytokines drive the formation of memory-like NK cell subsets via epigenetic rewiring and transcriptional regulation. Sci. Immunol. 9, eadk4893 (2024).","journal-title":"Sci. Immunol."},{"key":"2911_CR327","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1182\/blood.2021013972","volume":"139","author":"JJ Bednarski","year":"2022","unstructured":"Bednarski, J. J. et al. Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant. Blood. 139, 1670\u20131683 (2022).","journal-title":"Blood."},{"key":"2911_CR328","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1073\/pnas.0813192106","volume":"106","author":"MA Cooper","year":"2009","unstructured":"Cooper, M. A. et al. Cytokine-induced memory-like natural killer cells. Proc. Natl. Acad. Sci. USA. 106, 1915\u20131919 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"2911_CR329","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1158\/2159-8290.CD-20-0312","volume":"10","author":"MM Berrien-Elliott","year":"2020","unstructured":"Berrien-Elliott, M. M. et al. Multidimensional analyses of donor memory-like NK cells reveal new associations with response after adoptive immunotherapy for leukemia. Cancer Discov 10, 1854\u20131871 (2020).","journal-title":"Cancer Discov"},{"key":"2911_CR330","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1158\/2326-6066.CIR-24-0852","volume":"13","author":"Y Sun","year":"2025","unstructured":"Sun, Y. et al. Adaptive NK cells exhibit tumor-specific immune memory and cytotoxicity in ovarian cancer. Cancer Immunol. Res. 13, 1080\u20131097 (2025).","journal-title":"Cancer Immunol. Res."},{"key":"2911_CR331","doi-asserted-by":"publisher","first-page":"539","DOI":"10.4049\/jimmunol.2200851","volume":"211","author":"JR Lozada","year":"2023","unstructured":"Lozada, J. R., Zhang, B., Miller, J. S. & Cichocki, F. NK cells from human cytomegalovirus-seropositive individuals have a distinct metabolic profile that correlates with elevated mTOR signaling. J. Immunol. 211, 539\u2013550 (2023).","journal-title":"J. Immunol."},{"key":"2911_CR332","doi-asserted-by":"publisher","first-page":"101706","DOI":"10.1016\/j.smim.2022.101706","volume":"65","author":"M Lopez-Botet","year":"2023","unstructured":"Lopez-Botet, M. et al. Adaptive NK cell response to human cytomegalovirus: Facts and open issues. Semin Immunol 65, 101706 (2023).","journal-title":"Semin Immunol"},{"key":"2911_CR333","doi-asserted-by":"publisher","first-page":"eabc9801","DOI":"10.1126\/sciimmunol.abc9801","volume":"6","author":"TD Holmes","year":"2021","unstructured":"Holmes, T. D. et al. The transcription factor Bcl11b promotes both canonical and adaptive NK cell differentiation. Sci. Immunol. 6, eabc9801 (2021).","journal-title":"Sci. Immunol."},{"key":"2911_CR334","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41421-022-00467-2","volume":"8","author":"D Huang","year":"2022","unstructured":"Huang, D. et al. Lateral plate mesoderm cell-based organoid system for NK cell regeneration from human pluripotent stem cells. Cell Discov 8, 121 (2022).","journal-title":"Cell Discov"},{"key":"2911_CR335","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1182\/blood.2019000621","volume":"135","author":"H Zhu","year":"2020","unstructured":"Zhu, H. et al. Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity. Blood. 135, 399\u2013410 (2020).","journal-title":"Blood."},{"key":"2911_CR336","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","volume":"23","author":"Y Li","year":"2018","unstructured":"Li, Y., Hermanson, D. L., Moriarity, B. S. & Kaufman, D. S. Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell Stem Cell 23, 181\u2013192.e185 (2018).","journal-title":"Cell Stem Cell"},{"key":"2911_CR337","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13045-025-01712-3","volume":"18","author":"Y Lin","year":"2025","unstructured":"Lin, Y. et al. Engineered CRO-CD7 CAR-NK cells derived from pluripotent stem cells avoid fratricide and efficiently suppress human T-cell malignancies. J. Hematol. Oncol. 18, 57 (2025).","journal-title":"J. Hematol. Oncol."},{"key":"2911_CR338","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/s41551-025-01522-5","volume":"10","author":"F Hu","year":"2026","unstructured":"Hu, F. et al. Large-scale generation of iNK and CAR-iNK cells from CD34(+) haematopoietic stem and progenitor cells for adoptive immunotherapy. Nat. Biomed. Eng. 10, 765\u2013784 (2026).","journal-title":"Nat. Biomed. Eng."},{"key":"2911_CR339","doi-asserted-by":"publisher","first-page":"e1320630","DOI":"10.1080\/2162402X.2017.1320630","volume":"6","author":"JS Hoogstad-van Evert","year":"2017","unstructured":"Hoogstad-van Evert, J. S. et al. Umbilical cord blood CD34(+) progenitor-derived NK cells efficiently kill ovarian cancer spheroids and intraperitoneal tumors in NOD\/SCID\/IL2Rg(null) mice. Oncoimmunology. 6, e1320630 (2017).","journal-title":"Oncoimmunology."},{"key":"2911_CR340","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1158\/1078-0432.CCR-16-2981","volume":"23","author":"H Dolstra","year":"2017","unstructured":"Dolstra, H. et al. Successful transfer of umbilical cord blood CD34(+) Hematopoietic stem and progenitor-derived NK cells in older acute myeloid leukemia patients. Clin. Cancer Res. 23, 4107\u20134118 (2017).","journal-title":"Clin. Cancer Res."},{"key":"2911_CR341","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s00018-025-05727-4","volume":"82","author":"L Hooijmaijers","year":"2025","unstructured":"Hooijmaijers, L. et al. Good manufacturing practice production of an off-the-shelf CD34(+) progenitor-derived NK cell product with preserved anti-tumor functionality post-infusion in NOD\/SCID\/IL2Rg(null) mice. Cell. Mol. Life Sci. 82, 210 (2025).","journal-title":"Cell. Mol. Life Sci."},{"key":"2911_CR342","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ygyno.2025.11.006","volume":"204","author":"JS Hoogstad-van Evert","year":"2026","unstructured":"Hoogstad-van Evert, J. S. et al. Intraperitoneal infusion of stem cell-derived natural killer cells in recurrent epithelial ovarian cancer patients: results of the phase 1 INTRO-01 trial. Gynecol. Oncol. 204, 91\u201399 (2026).","journal-title":"Gynecol. Oncol."},{"key":"2911_CR343","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-025-01730-1","volume":"18","author":"HS Kim","year":"2025","unstructured":"Kim, H. S. et al. Directly reprogrammed NK cells driven by BCL11B depletion enhance targeted immunotherapy against pancreatic ductal adenocarcinoma. J. Hematol. Oncol. 18, 100 (2025).","journal-title":"J. Hematol. Oncol."},{"key":"2911_CR344","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1038\/s41551-021-00768-z","volume":"5","author":"HS Kim","year":"2021","unstructured":"Kim, H. S. et al. Directly reprogrammed natural killer cells for cancer immunotherapy. Nat. Biomed. Eng. 5, 1360\u20131376 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"2911_CR345","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1126\/science.1188063","volume":"329","author":"P Li","year":"2010","unstructured":"Li, P. et al. Reprogramming of T cells to natural killer-like cells upon Bcl11b deletion. Science. 329, 85\u201389 (2010).","journal-title":"Science."},{"key":"2911_CR346","doi-asserted-by":"publisher","first-page":"eadm8251","DOI":"10.1126\/sciimmunol.adm8251","volume":"10","author":"Y Li","year":"2025","unstructured":"Li, Y. et al. DNMT1 inhibition reprograms T cells to NK-like cells with potent antitumor activity. Sci. Immunol. 10, eadm8251 (2025).","journal-title":"Sci. Immunol."},{"key":"2911_CR347","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jim.2017.08.003","volume":"450","author":"MA Streltsova","year":"2017","unstructured":"Streltsova, M. A., Barsov, E., Erokhina, S. A. & Kovalenko, E. I. Retroviral gene transfer into primary human NK cells activated by IL-2 and K562 feeder cells expressing membrane-bound IL-21. J. Immunol. Methods. 450, 90\u201394 (2017).","journal-title":"J. Immunol. Methods."},{"key":"2911_CR348","doi-asserted-by":"publisher","first-page":"861681","DOI":"10.3389\/fimmu.2022.861681","volume":"13","author":"JL Oyer","year":"2022","unstructured":"Oyer, J. L. et al. Cryopreserved PM21-particle-expanded natural killer cells maintain cytotoxicity and effector functions in vitro and in vivo. Front. Immunol. 13, 861681 (2022).","journal-title":"Front. Immunol."},{"key":"2911_CR349","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jcyt.2016.02.006","volume":"18","author":"JL Oyer","year":"2016","unstructured":"Oyer, J. L. et al. Natural killer cells stimulated with PM21 particles expand and biodistribute in vivo: Clinical implications for cancer treatment. Cytotherapy. 18, 653\u2013663 (2016).","journal-title":"Cytotherapy."},{"key":"2911_CR350","doi-asserted-by":"publisher","first-page":"102975","DOI":"10.1016\/j.ebiom.2020.102975","volume":"59","author":"G Xie","year":"2020","unstructured":"Xie, G. et al. CAR-NK cells: a promising cellular immunotherapy for cancer. EBioMedicine. 59, 102975 (2020).","journal-title":"EBioMedicine."},{"key":"2911_CR351","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/leu.2017.226","volume":"32","author":"E Liu","year":"2018","unstructured":"Liu, E. et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 32, 520\u2013531 (2018).","journal-title":"Leukemia."},{"key":"2911_CR352","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1182\/bloodadvances.2023012202","volume":"8","author":"S Guo","year":"2024","unstructured":"Guo, S. et al. CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell malignancy. Blood Adv 8, 2635\u20132645 (2024).","journal-title":"Blood Adv"},{"key":"2911_CR353","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","volume":"614","author":"L Labanieh","year":"2023","unstructured":"Labanieh, L. & Mackall, C. L. CAR immune cells: design principles, resistance and the next generation. Nature. 614, 635\u2013648 (2023).","journal-title":"Nature."},{"key":"2911_CR354","doi-asserted-by":"publisher","first-page":"e010763","DOI":"10.1136\/jitc-2024-010763","volume":"13","author":"R Rahnama","year":"2025","unstructured":"Rahnama, R. et al. Single-chain variable fragment affinity tuning can optimize anti-AML CAR-NK cell functionality. J. Immunother. Cancer 13, e010763 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"2911_CR355","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41631-w","volume":"14","author":"D Li","year":"2023","unstructured":"Li, D. et al. Camel nanobody-based B7-H3 CAR-T cells show high efficacy against large solid tumours. Nat. Commun. 14, 5920 (2023).","journal-title":"Nat. Commun."},{"key":"2911_CR356","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41422-023-00789-0","volume":"33","author":"J Chen","year":"2023","unstructured":"Chen, J. et al. Tuning charge density of chimeric antigen receptor optimizes tonic signaling and CAR-T cell fitness. Cell Res 33, 341\u2013354 (2023).","journal-title":"Cell Res"},{"key":"2911_CR357","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long, A. H. et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med. 21, 581\u2013590 (2015).","journal-title":"Nat. Med."},{"key":"2911_CR358","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1158\/2326-6066.CIR-24-1347","volume":"13","author":"D Shukla","year":"2025","unstructured":"Shukla, D. et al. CAR binders affect CAR T-cell tonic signaling, durability, and sensitivity to target. Cancer Immunol. Res. 13, 867\u2013880 (2025).","journal-title":"Cancer Immunol. Res."},{"key":"2911_CR359","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41422-024-00936-1","volume":"34","author":"S Qiu","year":"2024","unstructured":"Qiu, S. et al. CAR-Toner: an AI-driven approach for CAR tonic signaling prediction and optimization. Cell Res 34, 386\u2013388 (2024).","journal-title":"Cell Res"},{"key":"2911_CR360","doi-asserted-by":"publisher","first-page":"e13683","DOI":"10.1111\/cpr.13683","volume":"57","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. Comparison of seven CD19 CAR designs in engineering NK cells for enhancing anti-tumour activity. Cell Prolif 57, e13683 (2024).","journal-title":"Cell Prolif"},{"key":"2911_CR361","doi-asserted-by":"publisher","first-page":"eadp4008","DOI":"10.1126\/sciadv.adp4008","volume":"11","author":"R Castellanos-Rueda","year":"2025","unstructured":"Castellanos-Rueda, R. et al. Dissecting the role of CAR signaling architectures on T cell activation and persistence using pooled screens and single-cell sequencing. Sci. Adv. 11, eadp4008 (2025).","journal-title":"Sci. Adv."},{"key":"2911_CR362","doi-asserted-by":"publisher","first-page":"4216","DOI":"10.1016\/j.cell.2023.08.013","volume":"186","author":"F Blaeschke","year":"2023","unstructured":"Blaeschke, F. et al. Modular pooled discovery of synthetic knockin sequences to program durable cell therapies. Cell. 186, 4216\u20134234.e4233 (2023).","journal-title":"Cell."},{"key":"2911_CR363","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/s41551-022-00895-1","volume":"6","author":"W Fu","year":"2022","unstructured":"Fu, W. et al. Synthetic libraries of immune cells displaying a diverse repertoire of chimaeric antigen receptors as a potent cancer immunotherapy. Nat. Biomed. Eng. 6, 842\u2013854 (2022).","journal-title":"Nat. Biomed. Eng."},{"key":"2911_CR364","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-023-06945-1","volume":"626","author":"E Vivier","year":"2024","unstructured":"Vivier, E. et al. Natural killer cell therapies. Nature. 626, 727\u2013736 (2024).","journal-title":"Nature."},{"key":"2911_CR365","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-022-02003-x","volume":"28","author":"Y Li","year":"2022","unstructured":"Li, Y. et al. KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape. Nat. Med. 28, 2133\u20132144 (2022).","journal-title":"Nat. Med."},{"key":"2911_CR366","doi-asserted-by":"crossref","first-page":"137","DOI":"10.20892\/j.issn.2095-3941.2025.0149","volume":"22","author":"Y Zhang","year":"2025","unstructured":"Zhang, Y. et al. A novel BaEVRless-LV packaging system for the production of lentiviral vectors for clinical-grade CAR-NK cell manufacturing. Cancer Biol. Med. 22, 137\u2013143 (2025).","journal-title":"Cancer Biol. Med."},{"key":"2911_CR367","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.3389\/fimmu.2019.02873","volume":"10","author":"ABL Colamartino","year":"2019","unstructured":"Colamartino, A. B. L. et al. Efficient and robust NK-cell transduction with baboon envelope pseudotyped lentivector. Front. Immunol. 10, 2873 (2019).","journal-title":"Front. Immunol."},{"key":"2911_CR368","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.3389\/fimmu.2019.02001","volume":"10","author":"R Bari","year":"2019","unstructured":"Bari, R. et al. A distinct subset of highly proliferative and lentiviral vector (LV)-transducible NK cells define a readily engineered subset for adoptive cellular therapy. Front. Immunol. 10, 2001 (2019).","journal-title":"Front. Immunol."},{"key":"2911_CR369","doi-asserted-by":"publisher","first-page":"13364","DOI":"10.3390\/ijms241713364","volume":"24","author":"V Golubovskaya","year":"2023","unstructured":"Golubovskaya, V. et al. CAR-NK cells generated with mRNA-LNPs kill tumor target cells in vitro and in vivo. Int. J. Mol. Sci. 24, 13364 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2911_CR370","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.omtm.2021.10.014","volume":"23","author":"Z Du","year":"2021","unstructured":"Du, Z., Ng, Y. Y., Zha, S. & Wang, S. PiggyBac system to co-express NKG2D CAR and IL-15 to augment the in vivo persistence and anti-AML activity of human peripheral blood NK cells. Mol. Ther. Methods Clin. Dev. 23, 582\u2013596 (2021).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"2911_CR371","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1016\/j.ymthe.2024.05.022","volume":"32","author":"T Bexte","year":"2024","unstructured":"Bexte, T. et al. Engineering of potent CAR NK cells using non-viral Sleeping Beauty transposition from minimalistic DNA vectors. Mol. Ther. 32, 2357\u20132372 (2024).","journal-title":"Mol. Ther."},{"key":"2911_CR372","doi-asserted-by":"publisher","first-page":"e20201529","DOI":"10.1084\/jem.20201529","volume":"218","author":"RS Huang","year":"2021","unstructured":"Huang, R. S., Lai, M. C., Shih, H. A. & Lin, S. A robust platform for expansion and genome editing of primary human natural killer cells. J. Exp. Med. 218, e20201529 (2021).","journal-title":"J. Exp. Med."},{"key":"2911_CR373","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.ymthe.2025.01.024","volume":"33","author":"K Shankar","year":"2025","unstructured":"Shankar, K. et al. Virus-free CRISPR knockin of a chimeric antigen receptor into KLRC1 generates potent GD2-specific natural killer cells. Mol. Ther. 33, 1014\u20131030 (2025).","journal-title":"Mol. Ther."},{"key":"2911_CR374","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41417-025-00872-1","volume":"32","author":"L Dai","year":"2025","unstructured":"Dai, L. et al. CRISPR knock-in of a chimeric antigen receptor into GAPDH 3\u2019UTR locus generates potent B7H3-specific NK-92MI cells. Cancer Gene Ther 32, 227\u2013239 (2025).","journal-title":"Cancer Gene Ther"},{"key":"2911_CR375","doi-asserted-by":"publisher","first-page":"100236","DOI":"10.1016\/j.crmeth.2022.100236","volume":"2","author":"M Naeimi Kararoudi","year":"2022","unstructured":"Naeimi Kararoudi, M. et al. Optimization and validation of CAR transduction into human primary NK cells using CRISPR and AAV. Cell Rep. Methods. 2, 100236 (2022).","journal-title":"Cell Rep. Methods."},{"key":"2911_CR376","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1016\/j.ymthe.2025.12.064","volume":"34","author":"K Wang","year":"2026","unstructured":"Wang, K. et al. Basic enables selection-free efficient knockin of large DNA in primary human T cells. Mol. Ther. 34, 2309\u20132323 (2026).","journal-title":"Mol. Ther."},{"key":"2911_CR377","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coi.2016.10.004","volume":"44","author":"J Rautela","year":"2017","unstructured":"Rautela, J. & Huntington, N. D. IL-15 signaling in NK cell cancer immunotherapy. Curr. Opin. Immunol. 44, 1\u20136 (2017).","journal-title":"Curr. Opin. Immunol."},{"key":"2911_CR378","doi-asserted-by":"publisher","first-page":"e010822","DOI":"10.1136\/jitc-2024-010822","volume":"13","author":"X Wang","year":"2025","unstructured":"Wang, X. et al. Co-expression of IL-15 and CCL21 strengthens CAR-NK cells to eliminate tumors in concert with T cells and equips them with PI3K\/AKT\/mTOR signal signature. J. Immunother. Cancer 13, e010822 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"2911_CR379","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-025-02158-2","volume":"10","author":"J Luo","year":"2025","unstructured":"Luo, J. et al. Neoleukin-2\/15-armored CAR-NK cells sustain superior therapeutic efficacy in solid tumors via c-Myc\/NRF1 activation. Signal Transduct. Target. Ther. 10, 78 (2025).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2911_CR380","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/j.ccell.2024.07.007","volume":"42","author":"M Shanley","year":"2024","unstructured":"Shanley, M. et al. Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD. Cancer Cell 42, 1450\u20131466.e1411 (2024).","journal-title":"Cancer Cell"},{"key":"2911_CR381","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47574-0","volume":"15","author":"A Berjis","year":"2024","unstructured":"Berjis, A. et al. Pretreatment with IL-15 and IL-18 rescues natural killer cells from granzyme B-mediated apoptosis after cryopreservation. Nat. Commun. 15, 3937 (2024).","journal-title":"Nat. Commun."},{"key":"2911_CR382","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1182\/blood.2020007748","volume":"137","author":"M Daher","year":"2021","unstructured":"Daher, M. et al. Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. Blood. 137, 624\u2013636 (2021).","journal-title":"Blood."},{"key":"2911_CR383","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.jcyt.2016.12.005","volume":"19","author":"ES Yvon","year":"2017","unstructured":"Yvon, E. S. et al. Cord blood natural killer cells expressing a dominant negative TGF-beta receptor: Implications for adoptive immunotherapy for glioblastoma. Cytotherapy. 19, 408\u2013418 (2017).","journal-title":"Cytotherapy."},{"key":"2911_CR384","doi-asserted-by":"publisher","first-page":"e142116","DOI":"10.1172\/JCI142116","volume":"131","author":"H Shaim","year":"2021","unstructured":"Shaim, H. et al. Targeting the \u03b1v integrin\/TGF-\u03b2 axis improves natural killer cell function against glioblastoma stem cells. J. Clin. Invest. 131, e142116 (2021).","journal-title":"J. Clin. Invest."},{"key":"2911_CR385","doi-asserted-by":"publisher","first-page":"eadp0004","DOI":"10.1126\/scitranslmed.adp0004","volume":"16","author":"B Kumar","year":"2024","unstructured":"Kumar, B. et al. BATF is a major driver of NK cell epigenetic reprogramming and dysfunction in AML. Sci. Transl. Med. 16, eadp0004 (2024).","journal-title":"Sci. Transl. Med."},{"key":"2911_CR386","doi-asserted-by":"publisher","first-page":"1231916","DOI":"10.3389\/fimmu.2023.1231916","volume":"14","author":"A Mac Donald","year":"2023","unstructured":"Mac Donald, A. et al. KLRC1 knockout overcomes HLA-E-mediated inhibition and improves NK cell antitumor activity against solid tumors. Front. Immunol. 14, 1231916 (2023).","journal-title":"Front. Immunol."},{"key":"2911_CR387","doi-asserted-by":"publisher","first-page":"100521","DOI":"10.1016\/j.medj.2024.09.010","volume":"6","author":"M Saetersmoen","year":"2025","unstructured":"Saetersmoen, M. et al. Targeting HLA-E-overexpressing cancers with a NKG2A\/C switch receptor. Med 6, 100521 (2025).","journal-title":"Med"},{"key":"2911_CR388","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1158\/1078-0432.CCR-20-1457","volume":"27","author":"H Liu","year":"2021","unstructured":"Liu, H. et al. CD19-specific CAR T cells that express a PD-1\/CD28 chimeric switch-receptor are effective in patients with PD-L1-positive B-cell lymphoma. Clin. Cancer Res. 27, 473\u2013484 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2911_CR389","doi-asserted-by":"publisher","first-page":"e006002","DOI":"10.1136\/jitc-2022-006002","volume":"11","author":"J Bi","year":"2023","unstructured":"Bi, J. et al. TIPE2 deletion improves the therapeutic potential of adoptively transferred NK cells. J. Immunother. Cancer 11, e006002 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"2911_CR390","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41586-026-10149-8","volume":"652","author":"L Yang","year":"2026","unstructured":"Yang, L. et al. OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours. Nature 652, 740\u2013751 (2026).","journal-title":"Nature"},{"key":"2911_CR391","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/s41590-026-02473-y","volume":"27","author":"YM Kim","year":"2026","unstructured":"Kim, Y. M. et al. Engineering NK and T cells with metabolite-sensing receptors to target solid tumors. Nat. Immunol. 27, 1039\u20131052 (2026).","journal-title":"Nat. Immunol."},{"key":"2911_CR392","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-63863-8","volume":"16","author":"F Liu","year":"2025","unstructured":"Liu, F. et al. Selective HLA knockdown and PD-L1 expression prevent allogeneic CAR-NK cell rejection and enhance safety and anti-tumor responses in xenograft mice. Nat. Commun. 16, 8809 (2025).","journal-title":"Nat. Commun."},{"key":"2911_CR393","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41587-020-0601-5","volume":"39","author":"F Mo","year":"2021","unstructured":"Mo, F. et al. Engineered off-the-shelf therapeutic T cells resist host immune rejection. Nat. Biotechnol. 39, 56\u201363 (2021).","journal-title":"Nat. Biotechnol."},{"key":"2911_CR394","doi-asserted-by":"publisher","first-page":"101889","DOI":"10.1016\/j.xcrm.2024.101889","volume":"6","author":"L Wang","year":"2025","unstructured":"Wang, L. et al. CD70-targeted iPSC-derived CAR-NK cells display potent function against tumors and alloreactive T cells. Cell Rep. Med. 6, 101889 (2025).","journal-title":"Cell Rep. Med."},{"key":"2911_CR395","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41577-022-00732-1","volume":"23","author":"NK Wolf","year":"2023","unstructured":"Wolf, N. K., Kissiov, D. U. & Raulet, D. H. Roles of natural killer cells in immunity to cancer, and applications to immunotherapy. Nat. Rev. Immunol. 23, 90\u2013105 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"2911_CR396","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ccell.2023.01.008","volume":"41","author":"F Carrette","year":"2023","unstructured":"Carrette, F. & Vivier, E. NKG2A blocks the anti-metastatic functions of natural killer cells. Cancer Cell 41, 232\u2013234 (2023).","journal-title":"Cancer Cell"},{"key":"2911_CR397","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ccell.2023.12.008","volume":"42","author":"J Wienke","year":"2024","unstructured":"Wienke, J. et al. Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy. Cancer Cell 42, 283\u2013300.e288 (2024).","journal-title":"Cancer Cell"},{"key":"2911_CR398","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.22.00227","volume":"40","author":"RS Herbst","year":"2022","unstructured":"Herbst, R. S. et al. COAST: an open-label, phase II, multidrug platform study of durvalumab alone or in combination with oleclumab or monalizumab in patients with unresectable, stage III non-small-cell lung cancer. J. Clin. Oncol. 40, 3383\u20133393 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2911_CR399","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1158\/1078-0432.CCR-25-0073","volume":"31","author":"J Fayette","year":"2025","unstructured":"Fayette, J. et al. INTERLINK-1: a phase III, randomized, placebo-controlled study of monalizumab plus cetuximab in recurrent\/metastatic head and neck squamous cell carcinoma. Clin. Cancer Res. 31, 2617\u20132627 (2025).","journal-title":"Clin. Cancer Res."},{"key":"2911_CR400","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41417-021-00303-x","volume":"29","author":"K Kohli","year":"2022","unstructured":"Kohli, K., Pillarisetty, V. G. & Kim, T. S. Key chemokines direct migration of immune cells in solid tumors. Cancer Gene Ther 29, 10\u201321 (2022).","journal-title":"Cancer Gene Ther"},{"key":"2911_CR401","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12528","volume":"7","author":"R Klose","year":"2016","unstructured":"Klose, R. et al. Targeting VEGF-A in myeloid cells enhances natural killer cell responses to chemotherapy and ameliorates cachexia. Nat. Commun. 7, 12528 (2016).","journal-title":"Nat. Commun."},{"key":"2911_CR402","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.it.2024.07.009","volume":"45","author":"Y Cho","year":"2024","unstructured":"Cho, Y. & Doh, J. The extracellular matrix in solid tumor immunotherapy. Trends Immunol 45, 705\u2013714 (2024).","journal-title":"Trends Immunol"},{"key":"2911_CR403","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32782-3","volume":"13","author":"EI Rivas","year":"2022","unstructured":"Rivas, E. I. et al. Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+ breast tumors. Nat. Commun. 13, 5310 (2022).","journal-title":"Nat. Commun."},{"key":"2911_CR404","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ccell.2016.06.025","volume":"30","author":"A Young","year":"2016","unstructured":"Young, A. et al. Co-inhibition of CD73 and A2AR adenosine signaling improves anti-tumor immune responses. Cancer Cell 30, 391\u2013403 (2016).","journal-title":"Cancer Cell"},{"key":"2911_CR405","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1016\/j.celrep.2019.04.091","volume":"27","author":"I Perrot","year":"2019","unstructured":"Perrot, I. et al. Blocking antibodies targeting the CD39\/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies. Cell Rep 27, 2411\u20132425.e2419 (2019).","journal-title":"Cell Rep"},{"key":"2911_CR406","doi-asserted-by":"publisher","first-page":"eabg5016","DOI":"10.1126\/sciadv.abg5016","volume":"7","author":"ZA Rizvi","year":"2021","unstructured":"Rizvi, Z. A. et al. High-salt diet mediates interplay between NK cells and gut microbiota to induce potent tumor immunity. Sci. Adv. 7, eabg5016 (2021).","journal-title":"Sci. Adv."},{"key":"2911_CR407","doi-asserted-by":"publisher","first-page":"116172","DOI":"10.1016\/j.celrep.2025.116172","volume":"44","author":"AM Weis","year":"2025","unstructured":"Weis, A. M. et al. A capsular polysaccharide from a healthy human microbiota member activates a Lag-3-NK cell axis to restrain colon cancer and augment immunotherapy. Cell Rep 44, 116172 (2025).","journal-title":"Cell Rep"},{"key":"2911_CR408","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-68490-5","volume":"17","author":"Y Chen","year":"2026","unstructured":"Chen, Y. et al. In situ self-assembled cell reservoir hydrogel for maneuvering multistage radioimmunotherapy. Nat. Commun. 17, 1784 (2026).","journal-title":"Nat. Commun."},{"key":"2911_CR409","doi-asserted-by":"publisher","first-page":"eadw9133","DOI":"10.1126\/sciadv.adw9133","volume":"11","author":"Z Zheng","year":"2025","unstructured":"Zheng, Z. et al. Ultrasoft hydrogel immune millirobot with multimodal locomotion. Sci. Adv. 11, eadw9133 (2025).","journal-title":"Sci. Adv."},{"key":"2911_CR410","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1182\/blood-2013-10-533398","volume":"123","author":"MK Gleason","year":"2014","unstructured":"Gleason, M. K. et al. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood. 123, 3016\u20133026 (2014).","journal-title":"Blood."},{"key":"2911_CR411","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1158\/1078-0432.CCR-13-0505","volume":"19","author":"A Wiernik","year":"2013","unstructured":"Wiernik, A. et al. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition. Clin. Cancer Res. 19, 3844\u20133855 (2013).","journal-title":"Clin. Cancer Res."},{"key":"2911_CR412","first-page":"274","volume":"28","author":"DA Vallera","year":"2013","unstructured":"Vallera, D. A. et al. Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells. Cancer Biother. Radiopharm. 28, 274\u2013282 (2013).","journal-title":"Cancer Biother. Radiopharm."},{"key":"2911_CR413","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1158\/1535-7163.MCT-12-0692","volume":"11","author":"MK Gleason","year":"2012","unstructured":"Gleason, M. K. et al. Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production. Mol. Cancer Ther. 11, 2674\u20132684 (2012).","journal-title":"Mol. Cancer Ther."},{"key":"2911_CR414","doi-asserted-by":"publisher","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","volume":"125","author":"A Rothe","year":"2015","unstructured":"Rothe, A. et al. A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood. 125, 4024\u20134031 (2015).","journal-title":"Blood."},{"key":"2911_CR415","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1158\/2326-6066.CIR-19-0837","volume":"8","author":"M Felices","year":"2020","unstructured":"Felices, M. et al. Potent cytolytic activity and specific IL15 delivery in a second-generation trispecific killer engager. Cancer Immunol. Res. 8, 1139\u20131149 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"2911_CR416","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1158\/1078-0432.CCR-15-2710","volume":"22","author":"DA Vallera","year":"2016","unstructured":"Vallera, D. A. et al. IL15 trispecific killer engagers (TriKE) make natural killer cells specific to CD33+ targets while also inducing persistence, in vivo expansion, and enhanced function. Clin. Cancer Res. 22, 3440\u20133450 (2016).","journal-title":"Clin. Cancer Res."},{"key":"2911_CR417","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.4143\/crt.2016.491","volume":"49","author":"JU Schmohl","year":"2017","unstructured":"Schmohl, J. U. et al. Engineering of anti-CD133 trispecific molecule capable of inducing NK expansion and driving antibody-dependent cell-mediated cytotoxicity. Cancer Res. Treat. 49, 1140\u20131152 (2017).","journal-title":"Cancer Res. Treat."},{"key":"2911_CR418","doi-asserted-by":"publisher","first-page":"102117","DOI":"10.1016\/j.xcrm.2025.102117","volume":"6","author":"H Lin","year":"2025","unstructured":"Lin, H. et al. Characterization and comparative analysis of multifunctional natural killer cell engagers during antitumor responses. Cell Rep. Med. 6, 102117 (2025).","journal-title":"Cell Rep. Med."},{"key":"2911_CR419","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1038\/s41587-022-01626-2","volume":"41","author":"L Gauthier","year":"2023","unstructured":"Gauthier, L. et al. Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123. Nat. Biotechnol. 41, 1296\u20131306 (2023).","journal-title":"Nat. Biotechnol."},{"key":"2911_CR420","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1038\/s41591-025-03640-8","volume":"31","author":"Y Nieto","year":"2025","unstructured":"Nieto, Y. et al. Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial. Nat. Med. 31, 1987\u20131993 (2025).","journal-title":"Nat. Med."},{"key":"2911_CR421","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1016\/j.tibtech.2025.11.006","volume":"44","author":"YR Li","year":"2025","unstructured":"Li, Y. R., Zhu, Y. & Yang, L. Clinical technology advances driving in vivo CAR therapy. Trends Biotechnol 44, 1821\u20131824 (2025).","journal-title":"Trends Biotechnol"},{"key":"2911_CR422","doi-asserted-by":"publisher","first-page":"105266","DOI":"10.1016\/j.ebiom.2024.105266","volume":"106","author":"TA Bui","year":"2024","unstructured":"Bui, T. A. et al. Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment. EBioMedicine. 106, 105266 (2024).","journal-title":"EBioMedicine."},{"key":"2911_CR423","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S0140-6736(25)01030-X","volume":"406","author":"J Xu","year":"2025","unstructured":"Xu, J. et al. In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma. Lancet. 406, 228\u2013231 (2025).","journal-title":"Lancet."},{"key":"2911_CR424","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1056\/NEJMc2509522","volume":"393","author":"Q Wang","year":"2025","unstructured":"Wang, Q. et al. In vivo CD19 CAR T-cell therapy for refractory systemic lupus erythematosus. N. Engl. J. Med. 393, 1542\u20131544 (2025).","journal-title":"N. Engl. J. Med."},{"key":"2911_CR425","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/s41591-026-04244-6","volume":"32","author":"N An","year":"2026","unstructured":"An, N. et al. In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study. Nat. Med. 32, 1257\u20131266 (2026).","journal-title":"Nat. Med."},{"key":"2911_CR426","doi-asserted-by":"publisher","first-page":"e2509698123","DOI":"10.1073\/pnas.2509698123","volume":"123","author":"Q Yin","year":"2026","unstructured":"Yin, Q. et al. Lipid nanoparticle-mediated in vivo generation of panCAR immune cells for solid tumor immunotherapy. Proc. Natl. Acad. Sci. USA. 123, e2509698123 (2026).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"2911_CR427","doi-asserted-by":"publisher","first-page":"102250","DOI":"10.1016\/j.xcrm.2025.102250","volume":"6","author":"Y Wang","year":"2025","unstructured":"Wang, Y. et al. Synergically enhanced anti-tumor immunity of in vivo panCAR by circRNA vaccine boosting. Cell Rep. Med. 6, 102250 (2025).","journal-title":"Cell Rep. Med."},{"key":"2911_CR428","doi-asserted-by":"publisher","first-page":"4937","DOI":"10.1016\/j.ymthe.2025.06.036","volume":"33","author":"JI Andorko","year":"2025","unstructured":"Andorko, J. I. et al. Targeted in vivo delivery of genetic medicines utilizing an engineered lentiviral vector platform results in CAR T and NK cell generation. Mol. Ther. 33, 4937\u20134952 (2025).","journal-title":"Mol. Ther."},{"key":"2911_CR429","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s13258-025-01733-9","volume":"48","author":"D Jung","year":"2026","unstructured":"Jung, D. et al. Synergistic antitumor activity of CAR-NK cells combined with CAR-macrophages for pancreatic cancer treatment. Genes Genom 48, 523\u2013532 (2026).","journal-title":"Genes Genom"},{"key":"2911_CR430","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/s41587-024-02282-4","volume":"43","author":"L Peng","year":"2025","unstructured":"Peng, L. et al. In vivo AAV-SB-CRISPR screens of tumor-infiltrating primary NK cells identify genetic checkpoints of CAR-NK therapy. Nat. Biotechnol. 43, 752\u2013761 (2025).","journal-title":"Nat. Biotechnol."},{"key":"2911_CR431","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2017-05-785659","volume":"130","author":"SO Ciurea","year":"2017","unstructured":"Ciurea, S. O. et al. Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation. Blood. 130, 1857\u20131868 (2017).","journal-title":"Blood."},{"key":"2911_CR432","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1002\/eji.201948375","volume":"50","author":"XY Zhao","year":"2020","unstructured":"Zhao, X. Y. et al. Expanded clinical-grade membrane-bound IL-21\/4-1BBL NK cell products exhibit activity against acute myeloid leukemia in vivo. Eur. J. Immunol. 50, 1374\u20131385 (2020).","journal-title":"Eur. J. Immunol."},{"key":"2911_CR433","doi-asserted-by":"publisher","first-page":"eabm1375","DOI":"10.1126\/scitranslmed.abm1375","volume":"14","author":"MM Berrien-Elliott","year":"2022","unstructured":"Berrien-Elliott, M. M. et al. Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia. Sci. Transl. Med. 14, eabm1375 (2022).","journal-title":"Sci. Transl. Med."},{"key":"2911_CR434","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41375-023-01849-5","volume":"37","author":"KH Lee","year":"2023","unstructured":"Lee, K. H. et al. The infusion of ex vivo, interleukin-15 and -21-activated donor NK cells after haploidentical HCT in high-risk AML and MDS patients-a randomized trial. Leukemia. 37, 807\u2013819 (2023).","journal-title":"Leukemia."},{"key":"2911_CR435","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13045-025-01669-3","volume":"18","author":"RM Shapiro","year":"2025","unstructured":"Shapiro, R. M. et al. First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancer. J. Hematol. Oncol. 18, 17 (2025).","journal-title":"J. Hematol. Oncol."},{"key":"2911_CR436","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1158\/2643-3230.BCD-25-0130","volume":"7","author":"P Lin","year":"2026","unstructured":"Lin, P. et al. CD70-targeting CAR NK cells overcome BCMA downregulation and improve survival in high-risk multiple myeloma models. Blood Cancer Discov 7, 234\u2013249 (2026).","journal-title":"Blood Cancer Discov"},{"key":"2911_CR437","doi-asserted-by":"publisher","first-page":"e004244","DOI":"10.1136\/jitc-2021-004244","volume":"10","author":"PL Bernard","year":"2022","unstructured":"Bernard, P. L. et al. Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity. J. Immunother. Cancer 10, e004244 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"2911_CR438","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1038\/s41375-023-01948-3","volume":"37","author":"J Jiang","year":"2023","unstructured":"Jiang, J. et al. Inserting EF1alpha-driven CD7-specific CAR at CD7 locus reduces fratricide and enhances tumor rejection. Leukemia. 37, 1660\u20131670 (2023).","journal-title":"Leukemia."},{"key":"2911_CR439","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00262-025-04196-9","volume":"74","author":"D Wang","year":"2025","unstructured":"Wang, D. et al. NKG2D CAR-NK adoptive cellular immunotherapy combined with or without PD-1 blockade in the treatment of patients with metastatic colorectal cancer: an exploratory study. Cancer Immunol. Immunother. 74, 341 (2025).","journal-title":"Cancer Immunol. Immunother."},{"key":"2911_CR440","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.ymthe.2019.03.011","volume":"27","author":"L Xiao","year":"2019","unstructured":"Xiao, L. et al. Adoptive transfer of NKG2D CAR mRNA-engineered natural killer cells in colorectal cancer patients. Mol. Ther. 27, 1114\u20131125 (2019).","journal-title":"Mol. Ther."},{"key":"2911_CR441","doi-asserted-by":"publisher","first-page":"e1119354","DOI":"10.1080\/2162402X.2015.1119354","volume":"5","author":"S Genssler","year":"2016","unstructured":"Genssler, S. et al. Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival. Oncoimmunology. 5, e1119354 (2016).","journal-title":"Oncoimmunology."},{"key":"2911_CR442","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13045-024-01525-w","volume":"17","author":"A Van den Eynde","year":"2024","unstructured":"Van den Eynde, A. et al. IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts. J. Hematol. Oncol. 17, 8 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"2911_CR443","doi-asserted-by":"publisher","first-page":"200777","DOI":"10.1016\/j.omton.2024.200777","volume":"32","author":"JH Yoon","year":"2024","unstructured":"Yoon, J. H. et al. Empowering pancreatic tumor homing with augmented anti-tumor potency of CXCR2-tethered CAR-NK cells. Mol. Ther. Oncol. 32, 200777 (2024).","journal-title":"Mol. Ther. Oncol."},{"key":"2911_CR444","doi-asserted-by":"publisher","first-page":"e186890","DOI":"10.1172\/jci.insight.186890","volume":"10","author":"MA Villalona-Calero","year":"2025","unstructured":"Villalona-Calero, M. A. et al. Interim report on engineered NK cell trial in lung cancer refractory to immune checkpoint inhibitors. JCI Insight 10, e186890 (2025).","journal-title":"JCI Insight"},{"key":"2911_CR445","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-61196-0","volume":"16","author":"V Picant","year":"2025","unstructured":"Picant, V. et al. Interleukin-35 impairs human NK cell effector functions and induces their ILC1-like conversion with tissue residency features. Nat. Commun. 16, 6135 (2025).","journal-title":"Nat. Commun."},{"key":"2911_CR446","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.stem.2024.06.009","volume":"31","author":"JL Thangaraj","year":"2024","unstructured":"Thangaraj, J. L., Coffey, M., Lopez, E. & Kaufman, D. S. Disruption of TGF-beta signaling pathway is required to mediate effective killing of hepatocellular carcinoma by human iPSC-derived NK cells. Cell Stem Cell 31, 1327\u20131343.e1325 (2024).","journal-title":"Cell Stem Cell"},{"key":"2911_CR447","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1111\/1759-7714.14523","volume":"13","author":"HJ Park","year":"2022","unstructured":"Park, H. J. et al. Two-year efficacy of SNK01 plus pembrolizumab for non-small cell lung cancer: expanded observations from a phase I\/IIa randomized controlled trial. Thorac. Cancer. 13, 2050\u20132056 (2022).","journal-title":"Thorac. Cancer."},{"key":"2911_CR448","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41392-025-02488-1","volume":"10","author":"Q Tan","year":"2025","unstructured":"Tan, Q. et al. Dynamic transcriptional immune landscape in response to NK-cell therapy combined with gemcitabine plus S-1 in advanced pancreatic cancer: a phase 1b\/2 trial. Signal Transduct. Target. Ther. 10, 381 (2025).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2911_CR449","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1158\/1078-0432.CCR-21-0164","volume":"27","author":"LN Kerbauy","year":"2021","unstructured":"Kerbauy, L. N. et al. Combining AFM13, a bispecific CD30\/CD16 antibody, with cytokine-activated blood and cord blood-derived NK cells facilitates CAR-like responses against CD30(+) malignancies. Clin. Cancer Res. 27, 3744\u20133756 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2911_CR450","first-page":"253.e251","volume":"29","author":"DH Yoon","year":"2023","unstructured":"Yoon, D. H. et al. Phase I study: safety and efficacy of an ex vivo-expanded allogeneic natural killer cell (MG4101) with rituximab for relapsed\/refractory B cell non-hodgkin lymphoma. Transpl. Cell Ther. 29, 253.e251\u2013253 e259 (2023).","journal-title":"Transpl. Cell Ther."},{"key":"2911_CR451","doi-asserted-by":"publisher","first-page":"6441","DOI":"10.1158\/1078-0432.CCR-17-0379","volume":"23","author":"SM Federico","year":"2017","unstructured":"Federico, S. M. et al. A pilot trial of humanized anti-GD2 monoclonal antibody (hu14.18K322A) with chemotherapy and natural killer cells in children with recurrent\/refractory neuroblastoma. Clin. Cancer Res. 23, 6441\u20136449 (2017).","journal-title":"Clin. Cancer Res."},{"key":"2911_CR452","doi-asserted-by":"publisher","first-page":"152786","DOI":"10.1016\/j.semarthrit.2025.152786","volume":"74","author":"A Nordmann-Gomes","year":"2025","unstructured":"Nordmann-Gomes, A. et al. CAR T-cell therapy in SLE: a systematic review. Semin Arthritis Rheum 74, 152786 (2025).","journal-title":"Semin Arthritis Rheum"},{"key":"2911_CR453","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.14336\/AD.2024.0579","volume":"16","author":"X Wang","year":"2024","unstructured":"Wang, X. et al. Rejuvenation strategy for inducing and enhancing autoimmune response to eliminate senescent cells. Aging Dis 16, 2273\u20132292 (2024).","journal-title":"Aging Dis"},{"key":"2911_CR454","doi-asserted-by":"publisher","first-page":"1701655","DOI":"10.3389\/fimmu.2025.1701655","volume":"16","author":"R Rosas-Campos","year":"2025","unstructured":"Rosas-Campos, R. et al. Above and beyond senescence and CAR T cell: advances and future perspectives. Front. Immunol. 16, 1701655 (2025).","journal-title":"Front. Immunol."},{"key":"2911_CR455","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41586-020-2403-9","volume":"583","author":"C Amor","year":"2020","unstructured":"Amor, C. et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature. 583, 127\u2013132 (2020).","journal-title":"Nature."},{"key":"2911_CR456","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s43587-023-00560-5","volume":"4","author":"C Amor","year":"2024","unstructured":"Amor, C. et al. Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction. Nat. Aging. 4, 336\u2013349 (2024).","journal-title":"Nat. Aging."},{"key":"2911_CR457","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jhep.2024.03.014","volume":"81","author":"CN Yashaswini","year":"2024","unstructured":"Yashaswini, C. N. et al. Phenotypes and ontogeny of senescent hepatic stellate cells in metabolic dysfunction-associated steatohepatitis. J. Hepatol. 81, 207\u2013217 (2024).","journal-title":"J. Hepatol."},{"key":"2911_CR458","doi-asserted-by":"publisher","first-page":"102209","DOI":"10.1016\/j.xcrm.2025.102209","volume":"6","author":"Z Zhang","year":"2025","unstructured":"Zhang, Z. et al. Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in vivo CAR-T therapy for inflamm-aging. Cell Rep. Med. 6, 102209 (2025).","journal-title":"Cell Rep. Med."},{"key":"2911_CR459","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1089\/rej.2022.0008","volume":"25","author":"AR Mendelsohn","year":"2022","unstructured":"Mendelsohn, A. R. & Larrick, J. W. Antiaging vaccines targeting senescent cells. Rejuvenation Res. 25, 39\u201345 (2022).","journal-title":"Rejuvenation Res."},{"key":"2911_CR460","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1038\/s43587-021-00151-2","volume":"1","author":"M Suda","year":"2021","unstructured":"Suda, M. et al. Senolytic vaccination improves normal and pathological age-related phenotypes and increases lifespan in progeroid mice. Nat. Aging. 1, 1117\u20131126 (2021).","journal-title":"Nat. Aging."},{"key":"2911_CR461","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16347-w","volume":"11","author":"S Yoshida","year":"2020","unstructured":"Yoshida, S. et al. The CD153 vaccine is a senotherapeutic option for preventing the accumulation of senescent T cells in mice. Nat. Commun. 11, 2482 (2020).","journal-title":"Nat. Commun."},{"key":"2911_CR462","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.medj.2024.03.016","volume":"5","author":"J Shu","year":"2024","unstructured":"Shu, J. et al. The enchanting canvas of CAR technology: unveiling its wonders in non-neoplastic diseases. Med. 5, 495\u2013529 (2024).","journal-title":"Med."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02911-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02911-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02911-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:10:50Z","timestamp":1792123850000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02911-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":462,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2911"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02911-1","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"13 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"451"}}